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Background: Despite a growing number of prescriptions for antidepressants (over 70 million in 2018),
there is uncertainty about when people with depression might benefit from antidepressant medication
and concern that antidepressants are prescribed unnecessarily.
Objectives: The main objective of the PANDA (What are the indications for Prescribing ANtiDepressAnts
that will lead to a clinical benefit?) research programme was to provide more guidance about when
antidepressants are likely to benefit people with depression. We aimed to estimate the minimal clinically
important difference for commonly used self-administered scales for depression and anxiety, and to
understand more about how patients respond to such assessments. We carried out an observational study
of patients with depressive symptoms and a placebo-controlled randomised controlled trial of sertraline
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versus placebo to estimate the treatment effect in UK primary care. The hypothesis was that the severity
and duration of symptoms were related to treatment response.
Design: The programme consisted of three phases. The first phase relied on the secondary analysis of
existing data extracted from published trials. The second phase was the PANDA cohort study of patients
with depressive symptoms who presented to primary care and were followed up 2, 4 and 6 weeks after a
baseline assessment. Both quantitative and qualitative methods were used in the analysis. The third phase
was a multicentre randomised placebo-controlled double-blind trial of sertraline versus placebo in patients
presenting to primary care with depressive symptoms.
Setting: UK primary care in Bristol, London, Liverpool and York.
Participants: Patients aged 18–74 years who were experiencing depressive symptoms in primary care.
Eligibility for the PANDA randomised controlled trial included that there was uncertainty about the benefits
about treatment with an antidepressant.
Interventions: In the PANDA randomised controlled trial, patients were individually randomised to
100 mg daily of sertraline or an identical placebo. The PANDA cohort study was an observational study.
Main outcome measures: Depressive symptoms measured using the Patient Health Questionnaire were
the primary outcome for the randomised controlled trial. Other outcomes included anxiety symptoms using
the Generalised Anxiety Disorder-7; depressive symptoms using the Beck Depression Inventory, version 2;
health-related quality of life; self-reported improvement; and cost-effectiveness.
Results: The secondary analysis of existing randomised controlled trials [GENetic and clinical Predictors
Of treatment response in Depression (GenPod), TREAting Depression with physical activity (TREAD)
and Clinical effectiveness and cost-effectiveness of cognitive Behavioural Therapy as an adjunct to
pharmacotherapy for treatment-resistant depression in primary care (CoBalT)] found evidence that the
minimal clinically important difference increased as the initial severity of depressive symptoms rose. Our
estimates of minimal clinically important difference were a 17% and 18% reduction in Beck Depression
Inventory scores for GenPod and TREAD, respectively. In CoBalT, a 32% reduction corresponded to the
minimal clinically important difference but the participants in this study had depression that had not
responded to antidepressants. In the PANDA study cohort, and from our analyses in existing data,
we found that the minimal clinically important difference varies considerably with the initial severity of
depressive and anxiety symptoms. Expressing the minimal clinically important difference as a percentage
reduction reduces this variation at higher scores, but at low scores the percentage reduction increased
substantially. The results from the qualitative studies pointed out many limitations of the Patient Health
Questionnaire-9 items in assessing change and recovery from depression. In the PANDA randomised
controlled trial, there was no evidence that sertraline resulted in a reduction in depressive symptoms within
6 weeks of randomisation, but there was some evidence of a reduction by 12 weeks. However, sertraline
led to a reduction in anxiety symptoms, an improvement of mental health-related quality of life and an
increased likelihood of reporting improvement. The mean Patient Health Questionnaire-9 items score at
6 weeks was 7.98 (standard deviation 5.63) in the sertraline group and 8.76 (standard deviation 5.86)
in the placebo group (5% relative reduction, 95% confidence interval –7% to 15%; p = 0.41). Of the
secondary outcomes, there was strong evidence that sertraline reduced anxiety symptoms (Generalised
Anxiety Disorder-7 score reduced by 17% (95% confidence interval 9% to 25%; p = 0.00005). Sertraline
had a high probability (> 90%) of being cost-effective at 12 weeks. The PANDA randomised controlled
trial found no evidence that treatment response or cost-effectiveness was related to severity or duration
of depressive symptoms. The minimal clinically important difference estimates suggested that sertraline’s
effect on anxiety, but not on depression, was likely to be clinically important.
Limitations: The results from the randomised controlled trial and the estimates of minimal clinically
important difference were not sufficiently precise to provide specific clinical guidance for individuals. We
had low power in testing whether or not initial severity and duration of depressive symptoms are related to
treatment response.
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Conclusions: The results of the trial support the use of sertraline and probably other selective serotonin
reuptake inhibitors because of their action in reducing anxiety symptoms and the likelihood of longer-term
benefit on depressive symptoms. Sertraline could be prescribed for anxiety symptoms that commonly occur
with depression and many patients will experience a clinical benefit. The Patient Health Questionnaire-9
items and similar self-administered scales should not be used on their own to assess clinical outcome, but
should be supplemented with further clinical assessment.
Future work: We need to examine the longer-term effects of antidepressant treatment. We need more
precise estimates of the treatment effects and minimal clinically important difference at different severities
to provide more specific guidance for individuals. However, the methods we have developed provide an
approach towards providing such detailed guidance.
Trial registration: Current Controlled Trials ISRCTN84544741 and EudraCT number 2013-003440-22.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme Grants
for Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 7, No. 10. See the NIHR Journals Library website for further project information.
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Plain English summary
There were over 70 million antidepressent prescriptions in England in 2018, and there are concerns thatthey are overprescribed. The aim of the PANDA (What are the indications for Prescribing ANtiDepressAnts
that will lead to a clinical benefit?) research programme was to provide general practitioners with improved
guidance to help them make recommendations about the likely response to antidepressants.
We carried out two studies. In the first, we recruited 558 people with depressive symptoms and followed
them for 6 weeks. We estimated a patient-centred measure of the minimal clinically important difference,
an improvement that would be recognised by the patient. We found that the minimal clinically important
difference was best expressed as about a 20% reduction in the patient’s initial symptoms, but at lower
symptoms the percentage change for the minimal clinically important difference became larger.
We also interviewed patients with open-ended interviews. They reported that the Patient Health
Questionnaire-9 items failed to fully capture their experience of recovery from depression. Some patients
struggled with how the questions were phrased and there was a lot of disagreement between self-reported
improvement and change in Patient Health Questionnaire-9 items score. We concluded that clinicians
should not rely on scales such as the Patient Health Questionnaire-9 items to assess improvement but
should use additional questions and further clinical assessment before deciding on improvement.
Our second study was a randomised clinical trial (on 653 participants) to investigate the clinical
effectiveness of sertraline, a commonly used first-line antidepressant. We found no evidence that sertraline
was more effective than a placebo (an identical inactive capsule) at reducing depression symptoms by
6 weeks, but by 12 weeks we found some evidence for a reduction in depressive symptoms. However, we
found strong evidence that sertraline was effective at reducing anxiety symptoms and that patients who
took sertraline were more likely to report improvement and better mental health overall. Sertraline is a
cheap intervention that had a high probability of being cost-effective. We found no evidence that the
severity and duration of patients’ depressive symptoms predicted their response to antidepressants or the
cost-effectiveness of treatment.
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Scientific summary
Background
There were over 70 million antidepressent prescriptions in England in 2018, with a substantial cost to the
NHS. Selective serotonin reuptake inhibitors are the first-line antidepressant recommended by UK National
Institute for Health and Care Excellence guidelines. However, there is little clinical guidance on when an
antidepressant should be prescribed, uncertainty about when patients might benefit and concerns that
antidepressants are prescribed unnecessarily.
Aims and objectives
The overall aim of the PANDA (What are the indications for Prescribing ANtiDepressAnts that will lead to
a clinical benefit?) research programme was to provide general practitioners with improved guidance that
would enable them to make recommendations about the probable response to antidepressants for patients
with depressive symptoms. We wanted to estimate the minimal clinically important difference for depressive
symptom questionnaires and understand more about how patients respond to such assessments. We carried
out a randomised controlled trial (the PANDA randomised controlled trial) that examined the cost-effectiveness
of sertraline compared with placebo. Our hypothesis was that the response to antidepressants compared with
placebo would increase with both the severity and duration of depressive symptoms. We conducted our
research in three phases.
Methods and results
Phase 1: using previously collected data
Aim 1a: using existing data to estimate the minimal clinically important difference for
the Beck Depression Inventory, version 2
We examined data from three existing randomised controlled trials [GENetic and clinical Predictors Of treatment
response in Depression (GenPod), TREAting Depression with physical activity (TREAD) and Clinical effectiveness
and cost-effectiveness of cognitive Behavioural Therapy as an adjunct to pharmacotherapy for treatment-resistant
depression in primary care (CoBalT)], which used a Global Rating of Change question and the Beck Depression
Inventory, version 2, to measure depressive symptoms. We estimated the minimal clinically important difference
by calculating the reduction in Beck Depression Inventory, version 2, scores in those who reported they
had improved. We found evidence that the minimal clinically important difference increased as the initial
severity of depressive symptoms rose and the minimal clinically important difference was better described as
a percentage reduction of the initial score rather than an absolute fixed value. Our estimates of minimal
clinically important difference were a 17%, 18% and 32% reduction for people with depression for GenPod,
TREAD and CoBalT, respectively.
Aim 1b: ‘mapping’ the relationship between different depression scales
We identified 31 RCTs that had included more than one depressive symptom, or health-related quality-of-life
scales. We used a novel method to compare the relative responsiveness of the scales that allowed estimation
of mapping coefficients that could translate treatment effects. We found evidence that, of the depression
measures, the Patient Health Questionnaire-9 items was the most responsive to change. A 1.0 standard
deviation treatment effect on the Beck Depression Inventory (the reference) was, on average, equivalent
to 1.52 standard deviations on the Patient Health Questionnaire-9 items (95% credibility interval 1.17 to
2.05 standard deviations) and 1.31 standard deviations on the Hamilton Rating Scale for Depression
(95% credibility interval 1.04 to 1.69 standard deviations).
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Aim 1c: value-of-information study to estimate the probable benefit of carrying out the
PANDA randomised controlled trial
We developed a novel economic model that incorporates the severity of depression as part of the decision-
making process. The model determined that treating patients with a severity score of ≥ 2 on the Hamilton
Rating Scale for Depression had the highest probability (> 65%) of being cost-effective at a £20,000
willingness-to-pay threshold. However, there was a lack of evidence at low levels of severity, and the
results relied on a number of assumptions. We concluded that the PANDA randomised controlled trial was
likely to be an efficient use of resources to reduce uncertainty in the most cost-effective treatment for such
patients (expected value of partial perfect information = £67.7M over a 10-year time horizon).
Phase 2: cohort study: using both quantitative and qualitative methods
We conducted a cohort study of 558 people who had presented with symptoms of depression or low mood
to their general practitioner in the previous 12 months. Practices were recruited in Bristol, Liverpool and
York. Potential participants were identified by searching the general practitioner electronic records and were
then invited to participate if they were aged 18–70 years and did not have comorbid psychosis, bipolar
disorder, eating disorders or substance dependence. Participants were followed up at 2, 4 and 6 weeks after
baseline, when they completed self-administered questionnaires assessing symptoms of depression and
anxiety (i.e. Beck Depression Inventory, version 2, Patient Health Questionnaire-9 items and Generalised
Anxiety Disorder-7) and were asked to rate their own improvement using a Global Rating of Change
question. The Global Rating of Change was assessed by asking patients ‘compared to when we last saw
you 2 weeks ago, how have your moods and feelings changed?’. Response options were ‘I feel a lot better’
(1), ‘I feel slightly better’ (2), ‘I feel about the same’ (3), ‘I feel slightly worse’ (4), or ‘I feel a lot worse’ (5).
The Clinical Interview Schedule – Revised was completed at baseline.
Aim 2a: estimates of the minimal clinically important difference in commonly used
self-administered questionnaires for depressive symptoms
In the PANDA cohort, we estimated the optimal threshold score for the Patient Health Questionnaire-9
items, Beck Depression Inventory, version 2, and Generalised Anxiety Disorder-7 (a measure of anxiety
symptoms), below which someone was more likely to report feeling better. This as the most robust estimate
of minimal clinically important difference as it also takes account of the variability of scores. The PANDA
cohort had a lower range of scores than those found in the previous analysis (see Aim 1a: using existing
data to estimate the minimal clinically important difference for the Beck Depression Inventory, version 2)
and we found that the size of the minimal clinically important difference, expressed as proportional
reduction, was larger for when initial severity of depressive symptoms was low. For those with an initial
score of 12 on the Patient Health Questionnaire-9 items, the minimal clinically important difference was
19.7%, but for those with an initial score of 4, the minimal clinically important difference was 48.2%.
Aim 2b: investigation of the changes reported by patients as they recover
from depression
Study 1: usefulness of the Patient Health Questionnaire-9 items in primary care to
determine meaningful symptoms of low mood – a qualitative study
We conducted a longitudinal qualitative study of 18 participants selected using the same criteria as the
PANDA cohort but with a purposive sampling strategy. The participants completed the Global Rating of
Change and the Patient Health Questionnaire-9 items using cognitive interviewing techniques at 2, 4 and
6 weeks after baseline. Participants reported that the Patient Health Questionnaire-9 items omits certain
symptoms that are important to people with depression. Participants translated the options on frequency
such that ‘several days’ was used to represent a higher intensity of symptom. Participants thought that the
Global Rating of Change was a good way of taking account of all the symptoms and changes that were
important to them.
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Study 2: variation in recognition of happy and sad facial expressions and self-reported
depressive symptom severity
Biases in the way that people process emotional information might be markers of recovery from depression
and it has been suggested that antidepressants work via their action on emotion-processing. In the PANDA
cohort, we administered a task concerned with identifying the emotional expression on morphed faces.
We found that depressive symptoms were associated with an increase in reporting happy faces when
ambiguous expressions were presented. There was no association between depressive symptoms and
recognition of sad faces.
Study 3: variation in the recall of socially rewarding information and depressive symptom
severity – a prospective cohort study
We investigated whether or not severity of depressive symptoms in the PANDA cohort was associated with
recall of positive and negative words, as a measure of emotional processing. We found evidence that, for
every increase in two positive words recalled, depressive symptoms were lower by –0.6 (95% confidence
interval –1.0 to –0.2) Beck Depression Inventory points, but there was no evidence for an association with
negative words. These findings suggest that people with more severe depressive symptoms recall less
positive information but negative information is unaffected, which is similar to the face recognition
findings above.
Aim 2c: to investigate disagreement between self-reported improvement and changes in
the scores on depressive symptom questionnaires
Study 1: why are there discrepancies between depressed patients’ Global Rating of
Change and scores on the Patient Health Questionnaire-9 items depression module?
A qualitative study of primary care in England
We identified participants from the PANDA cohort who reported a disagreement between the Global Rating
of Change and the change in scores on the Patient Health Questionnaire-9 items. We defined disagreement
as meaningful if scores changed by ≥ 15%, based on preliminary results. Of the first 86 participants from the
Liverpool site, 29 participants (34%) with the most pronounced disagreement took part in this qualitative
study. We identified four themes used by participants to explain the mismatch between the Global Rating of
Change and the Patient Health Questionnaire-9 items: (1) problems with the Patient Health Questionnaire-9
items and perceptions that the Global Rating of Change provided a more accurate assessment of current
mental state, (2) the impact of recent positive or negative life events, (3) personal understanding of depression
and coping mechanisms and (4) an inability to recall how they felt in the past.
Study 2: changes in self-administered measures of depression severity and patients’ own
perceptions of changes in their mood – a cohort study in primary care
This quantitative study in the PANDA cohort investigated the disagreement between changes in Patient
Health Questionnaire-9 items and Beck Depression Inventory, version 2, scores and responses to self-reported
improvement (Global Rating of Change). We used a minimal clinically important difference estimate of 20%.
We found that in a substantial proportion of patients (51% on the Patient Health Questionnaire-9 items scale
and 55% on the Beck Depression Inventory, version 2, scale), there was a clinically important disagreement
between their responses to the questionnaires and the Global Rating of Change. We found that participants
who reported anxiety and poor quality of life were less likely to report feeling better on the Global Rating of
Change after taking account of their change in depressive symptom score.
Phase 3: randomised controlled trial
Aim 3: severity and duration of depressive symptoms and response to antidepressants
(the PANDA trial) – a pragmatic randomised controlled trial in primary care
We conducted a pragmatic randomised multicentre double-blind placebo-controlled trial of patients from
179 primary care surgeries in four UK sites. Patients aged 18 to 74 years with reported depressive
symptoms were eligible if there was uncertainty about the benefit of an antidepressant. Patients were
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individually randomised to 100 mg daily of sertraline or placebo. The primary outcome was the Patient
Health Questionnaire-9 items score at 6 weeks. Secondary outcomes at 2, 6 and 12 weeks were depressive
symptoms and remission assessed using the Patient Health Questionnaire-9 items and the Beck Depression
Inventory, version 2, generalised anxiety disorder, mental and physical health-related quality of life, global
ratings of change, health-care costs and quality-adjusted life-years.
Our primary outcome analyses were of 550 patients (sertraline, n = 266; placebo, n = 284). The mean
Patient Health Questionnaire-9 items score at 6 weeks was 7.98 (standard deviation 5.63) in the sertraline
group and 8.76 (standard deviation 5.86) in the placebo group. In the sertraline group, Patient Health
Questionnaire-9 items scores were 5% (95% confidence interval –7% to 15%; p = 0.41) lower than in the
placebo group. There was no evidence that the treatment effect on the primary outcome varied according
to depression severity or duration. Of the secondary outcomes, there was strong evidence that sertraline
reduced anxiety symptoms (Generalised Anxiety Disorder-7 score reduced by 17%, 95% confidence interval
9% to 25%; p = 0.00005), improved mental, but not physical, health-related quality of life and self-reported
global improvement. There was weak evidence that depressive symptoms were reduced by sertraline at
12 weeks for both the Patient Health Questionnaire-9 items and the Beck Depression Inventory, version 2,
scales. There was some evidence that sertraline was more cost-effective than the placebo at a threshold of
£20,000 (incremental net monetary benefit £118, 95% confidence interval –£23 to £260) per quality-adjusted
life-year. Sertraline had a high probability (> 90%) of being cost-effective if the health system was willing
to pay > £20,000 per quality-adjusted life-year gained. We did not find evidence for any influence of
severity of symptoms or duration on treatment response or cost-effectiveness, but our analysis had low
statistical power.
Conclusions
Use of self-administered questionnaires in assessing depressive symptoms
There is a strong correlation between changes in Patient Health Questionnaire-9 items score and self-
reported improvement using the Global Rating of Change, and the Patient Health Questionnaire-9 items
appeared to be better at detecting average change than the Beck Depression Inventory, version 2, scale and
the Hamilton Rating Scale for Depression. However, we identified substantial disagreement between the
Global Rating of Change and changes in Patient Health Questionnaire-9 items score when considering
individual responses. Up to half of the people in our sample reported a disagreement between the Global
Rating of Change and changes on the Patient Health Questionnaire-9 items. Our qualitative research
also pointed out the limitation of these scales and supported the validity of the Global Rating of Change in
providing an overall measure of improvement. We conclude that the Patient Health Questionnaire-9 items
should not be used on its own to assess individual change. It is important for clinicians to supplement results
from the Patient Health Questionnaire-9 items with additional clinical assessment including open-ended
questions about any improvements.
We have estimated the minimal clinically important difference for the Beck Depression Inventory, version 2,
Patient Health Questionnaire-9 items and Generalised Anxiety Disorder-7 using a patient anchoring approach
in which we use the Global Rating of Change to estimate the threshold below which someone is more likely
to regard themselves as having improved. At higher initial severity, we found a minimal clinically important
difference of about 20%. However, at lower severities, the minimal clinically important difference increased
as a proportion; so for the lowest severity we examined, the minimal clinically important difference was as
large as 50% for the Patient Health Questionnaire-9 items. Our estimates were also imprecise at the lower
severities. This complex relationship between initial severity and minimal clinically important difference is an
important finding.
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Effectiveness and cost-effectiveness of sertraline
The PANDA randomised controlled trial did not find evidence that sertraline led to a clinically important
reduction in depressive symptoms at 6 weeks. However, we found strong evidence at 6 and 12 weeks that
sertraline reduced anxiety symptoms, that mental health-related quality of life improved and that participants
reported feeling better. There was some weak evidence that sertraline reduced depressive symptoms at
12 weeks. Sertraline is an inexpensive intervention that had a high probability (> 90%) of being cost-effective
compared with placebo at 12 weeks. Our results of an improvement in anxiety symptoms are to be expected
given previous findings, but the lack of an early effect on depressive symptoms is unexpected. We think
that the most likely explanation for this is that previous trials have mostly used the Hamilton Rating Scale
for Depression or similar measures of depression. The Hamilton Rating Scale for Depression is a relatively
unstandardised measure in which the observer can alter questions and it requires judgements; therefore, this
might have led to a halo effect on the rating of depressive symptoms because participants reported feeling
better as anxiety symptoms had reduced. We could not find evidence that the treatment response to
sertraline or cost-effectiveness varied according to severity or duration, but these analyses had low power.
We can apply our minimal clinically important difference results to the PANDA randomised controlled trial.
At 6 weeks’ follow-up, our findings suggest that there was a 5% (95% confidence interval –7% to 15%)
reduction in Patient Health Questionnaire-9 items scores and a 21% (95% confidence interval 11% to 30%)
reduction in Generalised Anxiety Disorder-7 scores. The relevant minimal clinically important difference for
Patient Health Questionnaire-9 items is 21% and for Generalised Anxiety Disorder-7 is 27%. We can
therefore conclude that, on average, sertraline does not lead to a clinically important difference in depressive
symptoms at 6 weeks, but the effect on anxiety symptoms is more consistent with such a clinically important
effect. A further implication from our minimal clinically important difference results is that, for those who
expect to have low scores at follow-up, the minimal clinically important difference is very large. About 30%
of the PANDA randomised controlled trial placebo group had a Generalised Anxiety Disorder-7 score of
≤ 3 at follow-up, which suggests that they would not have benefited from sertraline if they had received
that treatment.
An alternative approach would be to estimate the proportion who reported ‘feeling better’ using our
self-reported improvement question. This allows estimation of the number needed to treat. The number
needed to treat at 6 weeks was 8.5 (95% confidence interval 5.2 to 22.1) participants and at 12 weeks
6.4 (95% confidence interval 4.6 to 10.3) participants.
Trial registration
This trial is registered as ISRCTN84544741 and EudraCT number 2013-003440-22.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied
Research programme and will be published in full in Programme Grants for Applied Research; Vol. 7, No. 10.
See the NIHR Journals Library website for further project information.
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SYNOPSIS
Background
Depression is the leading cause of disability globally.1 Most people with depression or depressive symptoms
are treated in primary care and antidepressants are often the first-line treatment. There were over
70 million antidepressent prescriptions in England in 2018.2 There is much uncertainty about when people
with depression might benefit from an antidepressant and concern that antidepressants are overprescribed.
General practitioners (GPs) often feel under pressure to provide some treatment and have to make a difficult
decision about whether or not an individual will benefit from an antidepressant. The existing guidelines use
terms such as ‘mild’ or ‘moderate’ depression to guide prescription but do not specify what this means, and
such guidelines are not based on empirical studies. Identifying the patients who are most likely to respond to
an antidepressant would improve the management of depression in primary care as well as in other clinical
settings. This would reduce the inappropriate prescription of antidepressants in those less likely to respond,
and increase appropriate prescription in those more likely to respond.
The minimal clinically important difference
To make informed recommendations about when treatments are of benefit to patients, we must decide
what constitutes a clinically important treatment effect. There is no consensus about the size of a ‘clinically
important difference’ on continuous outcome scales. The National Institute for Health and Care Excellence
(NICE) guideline group, which includes service users, suggested that this difference was three points on the
Hamilton Rating Scale for Depression (HAMD),3 but did not provide any empirical justification.4 We need to
decide on a clinically important treatment effect before we can make recommendations about when selective
serotonin reuptake inhibitors (SSRIs) are of benefit and to estimate the sample size of a study. There have
been previous attempts to determine clinically important differences5,6 but these have relied on classifying
people as ‘well’ or ‘ill’ and then calculating the differences in score between the groups. However, these
metrics do not take into account the perspectives of the patient. We were interested in participants’ own
views about improvement to determine a clinically important difference. Our approach was to ask people
to rate their own improvement and then use this to calculate the difference in scores corresponding to a
change. This method has been used in relation to quality-of-life scales but, as far as we are aware, not in
relation to depression.7 There has been work comparing the results of self-administered questionnaires
with psychiatric diagnostic assessments.8 Our approach was therefore in contrast to these methods and
emphasises the patient’s perspective.
Measurement of depression
Another barrier to the development of evidence-based guidelines for antidepressant prescription in primary
care is the lack of a standardised measure of depressive symptoms that is easily implemented. Existing
studies on antidepressants mostly use rating scales, such as HAMD, that are difficult to standardise, are
designed for clinician administration and require training. It is extremely unlikely that these scales would
ever be used in primary care and this has never been proposed, to our knowledge. Shorter self-administered
scales, such as the Patient Health Questionnaire-9 items (PHQ-9),8 have been used in UK primary care and
in the NHS Improving Access to Psychological Treatment services. However, it is widely thought that the
PHQ-9 does not provide sufficiently good data to guide prescribing even if it is useful as an outcome
measure. The NICE CG90 depression guideline9 explicitly recommends not using the PHQ-9 and similar
scales alone for the purpose of guiding treatment.
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Short questionnaires, such as the PHQ-9, are unlikely to give accurate information to guide prescription,
but evidence suggests that they do perform well as a measure of outcome or change.10 However, this
symptom-based approach to measuring outcome has been challenged by the growing literature about
‘recovery’, largely from the perspective of people with psychosis. Two areas highlighted in this literature
include the concepts of hope and empowerment, the notion that the patient feels able to change.11
We are aware of only a limited literature concerned with ‘recovery’ in people who have experienced
depression.12 Malpass et al.13 have also interviewed people recovering from depression in relation to
change on the PHQ-9 and did identify some areas that were not well covered in that questionnaire.
These included anxiety along with ‘awareness’ and ‘ability to make changes’.
There is still some uncertainty about how antidepressants work but Harmer et al.14 have found that
antidepressants lead to changes early on in the processing of emotional information. Beck et al.15 first
proposed that negative interpretations, beliefs and memories play a key role in depression and developed
cognitive–behavioural therapy. Subsequently, the cognitive neuropsychological model of depression has
proposed that lower-level changes in emotional processing play a causal role in the genesis of symptoms
and precede changes in depressive symptoms.14 Simple tests, such as face recognition and word recall,
could be used alongside symptom measures to investigate changes in depression and complement
measures of symptoms. Existing studies have been small and used case–control designs that are prone to
selection bias. If we could confirm that emotion-processing tasks were related to depressive symptoms,
future research could see if the response to emotion-processing tasks could be used to predict clinical
response. We therefore also investigated associations between depressive symptom severity and emotional
processing and how this might change in recovery.
There are a wide range of existing outcome assessments of depressive symptoms, for example HAMD,
PHQ-9, Beck Depression Inventory, version 2 (BDI-II)16 and the Hospital Anxiety and Depression Scale (HADS).17
It would be useful to know how these scales inter-relate so that the results of clinical trials can be
compared with each other.18,19 If we could ‘map’ the scores on the scales against each other, this would
help with the interpretation of existing data and in the application of existing and future results to clinical
practice.
What factors are associated with response to antidepressants?
It has been proposed that antidepressants are more effective for patients with more severe depression,
but the evidence for this is inconsistent20–25 and recent large studies of individual patient data suggest no
influence of depression severity.23–25 On the other hand, a systematic review of patients with depressive
symptoms not meeting diagnostic criteria26 did not find evidence that antidepressants were effective.
However, the majority of the existing trials were not designed to investigate this hypothesis and exclude
patients who are below a certain severity threshold.27,28 A more general criticism is that the current
evidence is dominated by trials performed for regulatory purposes so it is difficult to generalise their results
to patients currently receiving treatment, mainly provided in primary care.
To help GPs decide whether or not to prescribe SSRIs, it is important to compare a SSRI with a placebo.
This becomes more rather than less important in less severe depression as the differences between
placebo and active medication are likely to be smaller than for more severe depression.20 By ‘response’
to antidepressants, we refer to the difference between the antidepressant and the placebo.
The two main diagnostic manuals, International Classification of Diseases, Tenth Edition (ICD-10),29 and
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),30 have similar, but not
identical, diagnostic criteria for a depressive episode (ICD-10) and major depression (DSM-IV). DSM-IV
also has a category of minor depression that requires fewer symptoms. As a rule, GPs do not use these
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diagnostic criteria and there is currently little empirical evidence that meeting either of these diagnostic
criteria can alone indicate whether or not antidepressants will be beneficial. There is a consensus that
depressive symptoms can be viewed along a continuum of severity, and, in population terms, ‘subthreshold’
symptoms are still a public health concern.31,32 It is therefore important to assess the severity of symptoms
along this continuum. People who do not meet diagnostic criteria might still benefit from antidepressant
treatment, or the converse.
There is evidence that antidepressants can be effective for people with dysthymia.33,34 Dysthymia is a US
term used in DSM-IV but not in ICD-10. It describes depressive symptoms of long duration (≥ 2 years) but
not meeting the diagnostic criteria for depression. NICE guidelines19 recommend SSRIs for persistent
subthreshold depressive symptoms but give no guidance on the duration of the persistence. We proposed,
as adopted by current UK guidelines,19,35 that symptom severity and duration of symptoms are two
separate dimensions that both might help to predict response to antidepressants.
The PANDA research programme
The overall aim of the PANDA (What are the indications for Prescribing ANtiDepressAnts that will lead to a
clinical benefit?) research programme was to provide GPs or other clinicians with improved guidance about
when antidepressants are most likely to result in a clinical benefit for patients with depressive symptoms in
primary care and be cost-effective for the NHS. The main hypothesis was that response to antidepressants
(compared with placebo) would increase with both the severity and duration of depressive symptoms.
The programme aimed to investigate whether or not there are thresholds of severity and duration above
which a clinically important response to antidepressants is most likely. In line with growing emphasis on
patient-centred care, ‘clinically important’ was defined as a reduction in depressive symptoms large enough
that patients would detect feeling better. An additional aim was therefore to establish, for the first time,
the reduction in depressive symptoms on self-administered depression questionnaires that is required for
patients to feel better. To assess severity and duration, we used a detailed, self-administered, computerised
assessment that could be easily implemented in primary care. Finally, we also wanted to investigate how
patients interpreted the questions in the current self-administered scales, to investigate how that related
to self-reported improvement and to investigate the relationship between depressive symptoms and the
underlying cognitive biases that are characteristic of depression.
A new randomised controlled trial (RCT) was required to provide this information, despite the wealth
of data available from previous placebo-controlled studies that have largely been carried out by the
pharmaceutical industry and are comprehensively summarised in Cipriani et al.28 First, the existing data
were mostly of a poor quality and were carried out decades ago for regulatory purposes rather than to
study clinical indications. Cipriani et al.28 noted that 78% of trials were industry funded and that, overall,
trials were of poor quality and small, with a mean sample size of 224 (across arms). In addition, 82% of
trials were also at moderate or high risk of bias and the larger more recent placebo-controlled trials
reported smaller effect sizes, perhaps reflecting more rigorous methods. Second, existing results on the
influence of depression severity on antidepressant response are in terms of HAMD scores. This is not
useful in primary care because of the training required. Even though we should be able to calculate
equivalent scores on measures such as the PHQ-9, more detailed assessments would provide a better
predictor of response than brief questionnaires. Third, existing data are unlikely to generalise to
the population currently receiving antidepressants in primary care in the UK or in other countries.
Most of the trials excluded people at lower levels of severity and the recruitment methods are usually
unknown. Finally, we are not aware of any existing data from previous studies on the influence of
duration of illness.
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The objectives of the PANDA research programme
The PANDA research programme consisted of three phases; the aims of each phase and the title of
corresponding PANDA papers are listed below.
Phase 1: using previously collected data
Aim 1a: to use existing data to estimate the minimal clinically important difference (MCID) for the BDI-II.
l See Appendix 1: Button et al.36
Aim 1b: to ‘map’ the relationship between different depression scales to estimate the scores on each scale
that correspond to the same severity of symptoms.
l See Appendix 2: Kounali et al.37
Aim 1c: to carry out a value-of-information study to estimate the probable benefit of carrying out a RCT as
described in phase 3.
l See Appendix 3: Thom et al.38
Phase 2: cohort study – using both quantitative and qualitative methods
Aim 2a: to estimate the MCID in commonly used self-administered questionnaires for depressive
symptoms.
l See Appendix 4
Aim 2b: to investigate the changes reported by patients as they recover from depression.
l See Appendix 5: Malpass et al.39
l See Appendix 6: Bone et al.40
l See Appendix 7: Lewis et al.41
Aim 2c: to investigate disagreement between self-reported improvement and changes in the scores on
depressive symptom questionnaires.
l See Appendix 8: Robinson et al.42
l See Appendix 9
Phase 3: randomised controlled trial
Aim 3: to investigate the severity and duration of depressive symptoms that are associated with a clinically
important response to sertraline in people with depression and whether or not these factors are associated
with the cost-effectiveness of sertraline.
l See Appendix 10: Salaminios et al.43
l See Appendix 11: Lewis et al.44
l See Appendix 12: Hollingworth et al.45
The inter-relationships between the three phases are summarised in Figure 1.
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Changes to the programme
1. In our research proposal, we originally had aimed to carry out a systematic review and individual patient
data meta-analysis to investigate the relationship between the severity of depressive symptoms and the
response to antidepressants. However, after the research programme was funded, an individual patient
data meta-analysis was published by Gibbons et al.23 using data provided by the pharmaceutical industry
and there have been more recent replications.24,25 Gibbons et al.23 analysed all the placebo-controlled
studies of the antidepressants fluoxetine and venlafaxine that were sponsored by the relevant pharmaceutical
company and had therefore obtained a complete and unbiased sample of the placebo-controlled trials.
As a result, we decided to abandon the original proposal for a systematic review in this area based on
literature searching and approaching authors for individual patient data.
2. With the resources that had originally been earmarked for the individual patient data meta-analysis,
we carried out an analysis of existing data to begin our study of the MCID (aim 1a and see Appendix 1)
and a value-of-information study (aim 1c and see Appendix 3). Previously published economic models
including that used in the NICE CG9019 did not consider treatment by baseline severity and none
modelled depression severity itself, so this required the development of an economic model in which
severity of depression was part of the decision-making process.
3. We also included some simple emotion-processing tasks in the PANDA cohort study. These tasks are
influenced by antidepressant medication and might indicate changes that occur during recovery from
depression that are not currently assessed by self-administered questionnaires. These tasks therefore
extended aim 2b and the relationship with depressive symptoms and changes in symptoms are reported
in Appendices 6 and 7.
Phase 2: cohort study – using both
quantitative and qualitative methods 
Phase 3: RCT
Develop these
analytical methods 
for cohort study
Identification of thresholds
of severity and duration
at which antidepressants
are most likely to lead to
a clinical benefit 
Clinical recommendations
for use of antidepressants
in primary care 
RCT testing the influence
of severity and duration
of depressive symptoms
on antidepressant response 
Phase 1: using previously
collected data
Qualitative 
investigation
Investigation of 
discrepancies between
PHQ-9 and global
ratings of change
Quantitative 
investigation
Preliminary study
estimating a clinically
important difference
Investigating changes 
reported by people
as they recover
from depression
Study to map
the relationship
between different
depression scales
Value-of- 
information 
study
Cohort study designed
to estimate a clinically 
important difference
FIGURE 1 The inter-relationships between the three phases.
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4. When originally devised, the primary aim of the RCT was to investigate the severity and duration of
symptoms associated with a clinically important response to sertraline, as stated in the protocol paper43
and on the International Standard Randomised Controlled Trial Number (ISRCTN) registry. However, it
was apparent towards the later stages of designing the RCT and in formulating the detailed analysis
plan46 (uploaded before any analyses were performed to http://discovery.ucl.ac.uk and approved by
the Trial Steering Committee) that we would have insufficient statistical power to estimate plausible
interaction effects that would allow us to investigate those aims. Our power calculation and primary
analysis (as stated in the analysis plan46) are therefore based on a primary aim to examine the clinical
effectiveness of sertraline versus placebo. Interactions between severity and duration at baseline and
treatment response were planned as exploratory.
5. In the original funding application, we used citalopram as our choice of antidepressant. However,
during the set-up stage, new guidance was released informing clinicians that citalopram can prolong
the QT interval, especially in higher doses. Although the risk was low, we decided to change the study
medication to sertraline, another commonly prescribed SSRI that is no longer under patent. There are
very few pharmacological differences between the SSRIs and we believe that the results of our study
can be applied to all SSRIs.
SYNOPSIS
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Phase 1: using previously collected data
Aim 1a: to use existing data to estimate minimal clinically important
difference from the patient perspective
Research aims
The aim of this study was to use existing data to estimate the MCID from the patient’s perspective, and to
investigate whether or not the MCID varied according to how severely ill patients were to begin with,
which we have called ‘baseline dependency’.
Methods for data collection
We used existing data from three RCTs [GENetic and clinical Predictors Of treatment response in Depression
(GenPod), TREAting Depression with physical activity (TREAD) and Clinical effectiveness and cost-effectiveness
of cognitive Behavioural Therapy as an adjunct to pharmacotherapy for treatment-resistant depression in
primary care (CoBalT)],47–49 in which we had asked patients a Global Rating of Change (GRC) question. All
these studies recruited individuals who met the ICD-10 criteria for depression. GENPOD compared citalopram
and reboxetine, TREAD evaluated an intervention designed to increase physical activity and CoBalt investigated
cognitive–behavioural therapy as an adjunctive treatment in people who had not responded to antidepressants.
As far as we are aware, these are the only trials that used the GRC. Each trial used the BDI-II as the primary
outcome, which provided an opportunity to estimate the MCID for the BDI-II. Each RCT investigated treatment
options for depression and followed participants over several months providing at least two time periods for
analysis. Data from 1039 patients who met the ICD-10 diagnostic criteria for depression were analysed.
Analysis
To test whether or not the MCID varied according to baseline severity, we assessed change in BDI-II scores
as both absolute (difference) and proportional reduction. Participants were dichotomised into ‘better’ and
‘not better’ (combining feeling the same and feeling worse) using the GRC. To examine whether or not
the MCID varied according to baseline severity of depression, and thus determine whether or not MCID
was best assessed in terms of absolute change or per cent reduction in scores from baseline, we used
generalised linear models. We used receiver operator characteristic (ROC) analysis to find the change in
BDI-II score (the ‘cut-off point’ or threshold) that optimally classifies those individuals who felt better and
those who did not.
Key findings
We found strong evidence that the size of the MCID depended on the initial severity of depressive
symptoms. Patients with more severe depressive symptoms at baseline required a larger change in their
BDI-II scores to report feeling better. Participants in the CoBalt study whose symptoms had not responded
to antidepressants needed to experience larger changes on the BDI-II (on average) to report feeling better.
Overall, for every 10-point increase in baseline severity on the BDI-II, the mean score associated with
feeling better increased by 4.8 points [95% confidence interval (CI) 0.9 to 8.5 points] on the BDI-II. There
was statistical evidence that the MICD was best assessed as a proportional reduction of scores rather than
an absolute fixed value.
Our best estimate for the MCID based on the ROC analyses provide the best estimates of MCID, with an
improvement from baseline of 17%, 18% and 32% for GenPod, TREAD and CoBalT, respectively. As
noted above, the MCID for CoBalt, in which the participants had depression that had not responded to
antidepressants, was larger than for the other two studies.
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Limitations
The study was a secondary data analysis from existing trials and the use of RCT data introduced regression
to the mean and this complicated the interpretation of the changes. The trials included only those who
met the ICD-10 criteria for depression so there were fewer data at lower levels of severity where there is
more controversy about the MCID.
Inter-relation with other parts of the programme
This study allowed us to develop our approach towards estimating the MCID in preparation for the PANDA
cohort study in phase 2. The MCID was also used to inform our power calculation for the RCT in phase 3.
The MCID estimate was also used for aim 2c, in which we investigated disagreements between self-reported
improvement and the changes in self-administered depression scales.
Aim 1b: ‘mapping’ the relationship between different depression scales
Research aims
The aim was to estimate the relative responsiveness of commonly used scales for depressive symptoms.
This allows comparison of treatment effects across different studies and also allowed us to draw conclusions
about the relative responsiveness of outcome measures that might not have been directly compared.
Methods for data collection
A search for all measures of depression, anxiety and quality-of-life outcomes was conducted in May 2011
in studies on the Cochrane Depression Anxiety and Neurosis review group’s register. We identified 31
placebo and usual-care controlled studies with clearly defined treatment and control groups that reported
two or more outcome measures of depression or quality of life. Eleven of the studies were drug trials and
the remaining studies were of psychological therapies. The depression measures included were the Beck
Depression Inventory (BDI), PHQ-9, Hamilton Rating Scale for Depression-17 items (HAMD-17),50 Hamilton
Rating Scale for Depression-24 items (HAMD-24)50 and Montgomery–Åsberg Depression Rating Scale
(MADRS).51 We also examined the EuroQol-5 Dimensions, five-level version (EQ-5D-5L),52 Short Form
questionnaire-36 items (SF-36) mental capacity score and SF-36 physical capacity score.53
Analysis
We used a new meta-analytic method that had been developed by our co-investigators54 that can be
interpreted as estimating the relative responsiveness of different scales. The data used in the study were
the mean treatment differences between active and control arms after 12 weeks’ follow-up or as close as
possible to that. If this was unavailable, we used the difference between the mean score at baseline and
follow-up. The pooled standard deviation (SD) at follow-up was used for standardisation, if available. If this
was not available, the pooled SD on the difference between the mean score at baseline and follow-up was
used. The analysis used methods that allowed for simultaneous estimation of treatment effects on continuous
outcomes and the ‘mappings’ between treatment effects in a Bayesian framework. The mappings are ratios
of the underlying treatment effects on their original scales. The mappings between standardised effects are
reported as relative responsiveness ratios.
Key findings
We found evidence that the PHQ-9 was most responsive to change following treatment of the depression
scales investigated. For example, a 1-SD unit treatment effect of BDI-II was equivalent to a 1.52-SD unit
effect on the PHQ-9 (95% credibility interval 1.17 to 2.05) and a 1.31-SD unit effect on HAMD-17 (95%
credibility interval 1.04 to 1.69). This is evidence that the PHQ-9 is more responsive to treatment changes
than the BDI, by a factor of 1.52, and the HAMD-17 is more responsive than the BDI, by a factor of 1.31.
The finding that the PHQ-9 was superior to the BDI agrees with a previous finding.55 There was evidence that
the generic EuroQol-5 Dimensions (EQ-5D) and SF-36 measures were less sensitive to change than the BDI.
PHASE 1: USING PREVIOUSLY COLLECTED DATA
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Limitations
Findings from this study are limited by its small size, the unrepresentative sample of trials that were
selected and the ability to generalise to other clinical situations.
Inter-relation with other parts of the programme
This study provided evidence that the PHQ-9 was more responsive to change after treatment than other
depression measures, supporting its use as an outcome measure in the PANDA RCT. The mapping
coefficients were also used in the value-of-information study (aim 1c) as the mapping coefficients can be
used to estimate quality-of-life differences when only depression measures have been used in the study.
Aim 1c: to assess the value of information from carrying out a
randomised controlled trial of antidepressants in depression of
mild severity
Research aims
Our aims were to develop an economic model that incorporates the severity of depression as part of
decision-making processes. This would lead to a recommendation of the most cost-effective threshold
above which to prescribe antidepressants and also an estimate of the value of a trial aiming to reduce
uncertainty in this decision.
Methods
We extracted trial data from those identified in earlier systematic reviews by Kirsch et al.,20 Fournier et al.22
and Gibbons et al.23 Cipriani et al.56 provided evidence on discontinuation rate in the first 12 weeks of
treatment. To address gaps in evidence for our economic model we obtained expert clinical opinion.
Analysis
The model is split into two components. The first was a continuous estimate of HAMD at the end of the
initial 12 weeks as a function of the initial score. This was based on a metaregression of the extracted
trials reporting treatment effect and baseline depression severity conducted using the Bayesian software
WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).57 This metaregression estimated proportional
treatment and placebo effects on depression severity on the HAMD scale.
This outcome of this model was then categorised into four depression severities: well is 0–7 HAMD, mild is
8–13 HAMD, moderate is 14–18 HAMD, and severe and very severe are > 19 HAMD. These four states
formed a Markov model58 that extrapolated patient progress over a further 2 years in eight 12-week cycles.
The HAMD for each state was mapped to the EQ-5D using the results of aim 1b, giving quality-adjusted
life-years (QALYs) for each cycle. Total QALYs and costs were calculated and gave the incremental net
benefit for each treatment strategy. The expected value of partial perfect information (EVPPI), which is the
improvement to decision-making if uncertainty on a selection of input parameters to the model were removed,
was used to determine an upper bound on the value of collecting further evidence.59
Key findings
The metaregression estimated that patients on antidepressants had an additional 12% (95% credibility
interval 3% to 21%) decrease in 6-week HAMD versus placebo. The economic model determined that
treating patients with a severity score of ≥ 2 on HAMD had the highest probability (> 65%) of being
cost-effective at a £20,000 willingness-to-pay threshold.
A short-term trial investigating the relation between treatment effect and severity and quality of life in
depression patients had an EVPPI of £67.7M over a 10-year time horizon. This suggested that the
proposed PANDA trial was potentially cost-effective.
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Limitations
There was little evidence on treatment effects in low-severity patients, but our analysis had assumed that
the relationship with severity held across the whole range of HAMD scores. We were reliant on clinical
opinion for some important values affecting costs. Finally, the EVPPI provides an upper bound on the value
of a trial as it assumes the removal of all uncertainty on a subset of parameters. Expected value of sample
information estimates the value of reduced uncertainty on a subset and is related to a specified sample size
and trial design; expected value of sample information would be necessary for a more accurate assessment
of trial value.60
Inter-relation with other parts of the programme
We estimated that the PANDA RCT (phase 3 of the programme grant) had the potential to be cost-effective
and the absolute expected value of perfect information estimates would vary from approximately £70M to
£95M between the models. The metaregression results of previous trials informed our power calculations
for the RCT.
PHASE 1: USING PREVIOUSLY COLLECTED DATA
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Phase 2: the PANDA cohort study –
using both quantitative and
qualitative methods
Aim 2a: estimating a clinically important difference in commonly used
self-administered questionnaires for depressive symptoms
Research aims
The aim of this study was to estimate the MCID for the PHQ-9, the BDI-II and the Generalised Anxiety
Disorder-7 (GAD-7) using an anchoring method in which participants were asked to retrospectively report
improvement or worsening on a GRC question. We also investigated whether or not the MCID varied
according to the initial severity of symptoms.
Methods for data collection
The PANDA cohort consisted of patients who had presented to UK primary care surgeries with depressive
symptoms or disorder, or depressed mood, during the previous year. Participants had a range of depressive
symptoms and were recruited from one population, reducing selection bias. Overall, 7721 patients were
sent an information letter in the post and 1470 (19%) replied (Figure 2). Of these, 821 were willing to be
contacted, 23 (3%) of whom were ineligible. The remaining 798 were contacted to arrange an interview
and 563 consented to take part in the cohort study. Data on our measures were collected at four time
points. At time 1, 559 people provided data (four could not be contacted), with corresponding figures at
follow-up at 2, 4 and 6 weeks of 476 (85%), 443 (79%) and 430 (77%), respectively. For this analysis we
used data from 400 participants who gave complete data on all follow-ups.
The participants were asked to rate their own improvement using a GRC question. The GRC was assessed
by asking patients ‘compared to when we last saw you 2 weeks ago, how have your moods and feelings
changed?’ Response options were ‘I feel a lot better’ (1), ‘I feel slightly better’ (2), ‘I feel about the same’
(3), ‘I feel slightly worse’ (4) and ‘I feel a lot worse’ (5). These ratings were compared with the changes in
the score on the self-administered questionnaires BDI-II, PHQ-9 and GAD-7. This enabled us to calculate
the change in scores (on the questionnaires) that corresponded to an improvement in patients’ GRC. To
assess the reliability of the GRC, the question was completed twice by the participants at each time point.
The participants completed the Clinical Interview Schedule – Revised (CIS-R)61 at baseline only. The data
were used to derive the diagnosis of depression and its severity.
Analysis
We analysed data from 400 participants with complete data on the CIS-R, PHQ-9, BDI-II, GAD-7 and GRC.
We assessed reliability of the GRC scale by quantifying the two repeated assessments completed by the
participant at each follow-up in absolute and relative terms. We used beta regression to estimate the
changes in depressive symptoms measured by the BDI-II and the PHQ-9 over three follow-ups in each GRC
category and according to three categories of the CIS-R score. This was an improvement on our previous
analysis as it allowed us to model variability and means.
Key findings
We estimated the threshold below which the participant was more likely to report feeling better than
feeling the same using a ROC analysis. The estimates were provided for three severity bands, determined by
the baseline CIS-R score. The average initial scores for the three bands on the PHQ-9 were 4.1, 7.8 and 12.2.
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The range of scores therefore extended our study of MCID to lower ranges of severity than our earlier study
(aim 1a, see Appendix 1). The MCID as a percentage appeared to increase for the lower severities. For example,
in the lowest severity band, the MCID for the PHQ-9 was 48% (95% CI 37% to 65%), whereas in the most
severe band it was 19% (95% CI 16% to 24%). There was still considerable uncertainty about the MCID
at lower severities. For the GAD-7, the corresponding figures were 72% (95% CI 55% to 97%) and 9%
(95% CI 7% to 11%).
Limitations
There was relatively low power in this cohort because there was little change in symptoms between the
follow-up points. We had a low response rate in the cohort, but one would not expect any selection bias
to affect the estimates. The participants who ‘felt the same’ on the GRC still had a drop in score and it is
not clear why this occurred.
Total number
of replies
(n = 1470)
Interested
(n = 798)
Consented
(n = 563)
Baseline
• Completed, n = 559
• Withdrew before baseline, n = 4
• Withdrew after baseline, n = 83
Not interested
(n = 649)
Follow-up 1
• Completed, n = 476
• Withdrew after follow-up 1,
   n = 33
Follow-up 2
• Completed, n = 443
• Withdrew after follow-up 2,
   n = 13
Interested
54%
Consented
70%
Baseline
99%
Follow-up 1
85%
Follow-up 2
79%
Follow-up 3
• Completed, n = 430
Follow-up 3
76%
Total withdrawals
(n = 113)
Withdrawals
20%
Follow-up 1
• Completed, n = 18
• Withdrew after follow-up 1,
   n = 2
Substudy 1
• Completed, n = 29
Substudy 2
(n = 18)
Follow-up 2
• Completed, n = 16
• Withdrew after follow-up 2,
   n = 2
Follow-up 3
• Completed, n = 14
• Not eligible, n = 23
FIGURE 2 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram: PANDA cohort study.
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Inter-relation with other parts of the programme
The MCID is essential if we are to give guidance to patients and doctors about whether or not
antidepressants should be prescribed. The aim of both MCID studies (aims 1a and 2a) was to develop,
for the first time, a patient-centred measure of the change in depressive symptoms required to achieve a
clinical benefit. These data will be able to help interpret the results of the PANDA RCT as well as being an
output in their own right for other investigators.
Our approach towards estimating the MCID was based on an average within-person change related to
improvement. However, the results from RCTs provide an estimate based on a comparison between groups.
Applying our MCID estimate to a RCT result therefore rests on a counterfactual argument in which the
outcome were that individual to receive a placebo is contrasted with the outcome were that individual to
receive the active treatment. In other words, the patient is told ‘if you received the treatment you would
(on average) be X points lower on the PHQ-9 and (on average) that is a difference that people regard as
important’. Using this argument allows clinicians to make treatment recommendations for individual
patients under counterfactual arguments resting on the trial’s generalisability. We describe the probability
that a patient who ‘feels better’ has a reduction in depression score scale of greater than or equal to the
MCID. It is natural to compare the expected benefit from an intervention tested in a RCT with that
minimum difference. It gives us an idea of the improvement needed for the patient to perceive any benefit.
Aim 2b: to investigate the changes reported by patients as they recover
from depression
We carried out three studies to investigate this aim. First, we carried out a qualitative investigation of the
meaningfulness of the PHQ-9 in determining meaningful symptoms of low mood. We also examined
the processing of emotional information and how this varied with depressive symptoms and over time.
Emotion-processing is a key abnormality in depression and influenced by antidepressant medication.14
The second study investigated the variation of emotional face recognition in relation to depressive symptoms.
Finally, the third study examined variation in recall of socially rewarding information according to depressive
symptoms.
Study 1: a qualitative investigation of the meaningfulness of the PHQ-9 in determining
meaningful symptoms of low mood
Research aims
To explore differences between the way patients comprehend and map their answer to the options on the
questionnaire. A secondary aim was to investigate whether or not patients shift over time in how they
comprehend items on the questionnaire or find them problematic to answer, in relation to their own
changing symptoms. The substudy also examined the content of responses and their meaning to the
participants.
Methods of data collection
This was a longitudinal qualitative substudy nested within the PANDA cohort study, which included
18 participants who completed the baseline appointment at the Bristol site. A purposive sampling strategy
was used to ensure that there was a range of participants of differing ethnicity and sex and sociodemographic
differences were presented. The participants were interviewed using cognitive interviewing techniques at 2,
4 and 6 weeks after their baseline. At each interview the participants were invited to complete the GRC
question and the PHQ-9 while thinking aloud what was going through their minds. Non-directive, open
verbal probing as well as observation probes were used (e.g. ‘You’re hesitating; can you tell me why?’,
which was followed by targeted probes, such as ‘What does that term mean to you?’). Forty-eight digitally
recorded interviews were recorded and analysed.
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Analysis
The analysis used was consistent to that used in cognitive interview framework analysis.62 A Microsoft
Excel® (Microsoft Corporation, Redmond, WA, USA) grid was created to analyse the digital audio files; the
grid contained 18 column headings, each heading denoting ‘comprehension’ or ‘answer mapping’ for
each item on the PHQ-9. Additional columns summarised the data from the card-sorting exercise and the
GRC question. Participants were listed in rows, where each row represented a different time point.
Key findings
The study provided evidence that the PHQ-9 may be missing the presence and/or intensity of certain
symptoms that are meaningful to patients. For instance, participants translated the options on frequency
into their own meaningful measure of intensity; for example, ‘several days’ was used to represent a low
level of intensity rather than the actual number of days a certain symptom was present. The triple- or
double-barrelled questions were problematic for participants who felt that they could respond differently
to each part of the question. For example, item 9 on the PHQ-9 asks if patients have been bothered with
‘thoughts that you would be better off dead, or hurting yourself in some way’. The participants regarded
the GRC as a good way of summarising their situation overall, in contrast to the PHQ-9, which addressed
only some of the important changes.
Limitations
The cognitive interviewing technique is still developing as a framework and the approaches to analysis of
the data collected of cognitive interview data are being debated.63 This was a small sample looking at a
limited range of questions.
Inter-relation with other parts of the programme
This study helps us to understand some of the limitations of the PHQ-9 from the perspective of patients.
It provides evidence that the GRC item has validity from the perspective of the patients and indicates the
weaknesses of the PHQ-9 in assessing individual change.
Study 2: variation in emotional face recognition and depressive symptom severity
Research aims
The aim was to investigate whether or not processing of happy and sad facial expressions was associated
with the severity of depressive symptoms, cross-sectionally and longitudinally.
Methods of data collection
In this study, we examined the data from the computerised facial recognition task that was completed
by the PANDA cohort participants (n = 509) at baseline, then at 2 and 4 weeks. The participants were
presented with ‘morphed’ faces with varying degrees of emotional intensity. The correct responses were
classified as ‘hits’ and incorrect responses as ‘false alarms’. Accuracy and response bias were measures for
facial expressions of varying emotional intensities.
Analysis
Analyses were conducted using multilevel or mixed-effects linear regression models to calculate concurrent
and longitudinal associations between hits, false alarms and depressive symptoms separately for happy and
sad faces.
Key findings
For every additional face incorrectly classified as happy (positive emotion bias), concurrent PHQ-9 scores
reduced by 0.05 of a point (95% CI –0.10 to 0.002; p = 0.06). This association was strongest for more
ambiguous facial expressions. There was no evidence for associations between sad face recognition and
concurrent depressive symptoms, or between happy or sad face recognition and subsequent depressive
symptoms or antidepressant use. We concluded that as the severity of depressive symptoms increased
there was a reduced tendency to see positive images but there was no influence on negative images.
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Limitations
The sample excluded people with depression who had not visited their GP and we had a low response
rate. However, the inclusion of participants did not depend on emotion recognition, so this is unlikely to
have biased any associations between emotion recognition and depressive symptoms. There was little
change in our cohort so we cannot exclude the possibility of longitudinal associations between facial
expression recognition and depressive symptoms.
Inter-relation with other parts of the programme
The results indicated that, as depressive symptoms increased, people became less likely to report that an
ambiguous facial expression was happy. This has important implications for understanding how people with
depression might respond to social circumstances. We demonstrated that this effect occurred over the whole
range of depressive symptom severity. Future research could identify whether or not emotion-processing
performance could be used to predict response to antidepressants.
Study 3: variation in the recall of socially rewarding information and depressive
symptom severity
Research aims
The aim was to investigate whether depressive symptoms are associated with recall for socially rewarding
(positive) or socially critical (negative) information.
Methods of data collection
This study also used the data from the PANDA cohort and, as in the previous study of facial recognition,
positive and negative recall were assessed at three time points: baseline and 2 and 4 weeks. On each
occasion, participants were presented with 20 likeable and 20 unlikeable faces on a computer screen in a
random order. Participants had to rate whether these were likeable or unlikeable and, after a short gap,
were asked to recall any of the words that were presented.
Analysis
Analyses were conducted using multilevel mixed-effects models to calculate concurrent and longitudinal
associations between the number of positive and negative words recalled and depressive symptoms,
before and after adjustment for confounders (n = 524).
Key findings
We found evidence for a concurrent association between increased recall of positive words and reduced
severity of depressive symptoms: for every increase in two positive words recalled, depressive symptoms
reduced by 0.6 (95% CI –1.0 to –0.2) BDI points. There was no evidence of an association between
depressive symptoms and negative recall (–0.1, 95% CI –0.5 to 0.3). Longitudinally, we found more
evidence that increased positive recall was associated with reduced depressive symptoms than vice versa.
Limitations
Although the analysis was conducted on the largest sample to date of emotional processing and depressive
symptoms, the cohort study had a low response rate, which might have introduced a selection bias.
Although different words were used at each time point, after the first assessment participants would have
expected the incidental recall task. This could have led to increased recall, but we did not observe this.
Aim 2c: to investigate disagreement between self-reported improvement
and changes in the scores on depressive symptom questionnaires
We used quantitative and qualitative methods to identify those aspects of recovery that are currently
missed by questionnaires.
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Study 1: why are there discrepancies between depressed patients’ Global Rating of Change
and scores on the PHQ-9 depression module? A qualitative study in primary care
Research aims
The aim of this qualitative study was to investigate why there are discrepancies between depressed
patients’ GRC in their mood and their scores on the PHQ-9. Patients were interviewed regarding the
source and meaning of mismatches between their GRC and their PHQ-9 scores.
Methods of data collection
This study was nested within the larger PANDA cohort study in which participants completed the GRC
and a PHQ-9 at four time points, each 2 weeks apart. We examined data from the first 86 participants in
Liverpool who had completed all study assessments. ‘Mismatch’ was defined as a disagreement between a
patient’s GRC and a meaningful change in their PHQ-9 scores between that time point and the preceding
one. We classified a meaningful change as a 15% reduction or increase in scores, based on preliminary
MCID estimates from the programme. Of the 86 participants selected, 44 (51%) were identified as cases
of mismatch. The 32 participants with the most pronounced mismatch were invited to participate in
the qualitative substudy. Qualitative interviews were audiotaped and transcribed with 29 participants.
The interview centred on five key topics: experiences of depression, experiences and expectations of
treatments, how effective they thought the questionnaires were (e.g. the PHQ-9), reasons for their
mismatch and social factors.
Analysis
Interpretative phenomenological analysis (IPA) was used to guide the analysis. This enabled us to focus on
the individual accounts before moving to identify more general themes in the data. All transcripts were
coded to identify initial themes, and then further analysed to formulate superordinate and subthemes.
Key findings
We identified four superordinate themes as explanations for disagreement:
1. There were limitations in the questions asked by the PHQ-9 and a lack of questioning about intensity
such that the GRC provided a more accurate assessment of current mental state. The PHQ-9 does not
ask about some depressive symptoms, such as interacting with people, lack of libido and inability to
cope at work. It also does not enquire about comorbid symptoms such as anxiety, PTSD symptoms and
physical illnesses.
2. The impact of recent positive or negative life events could affect their responses but was not captured
by the PHQ-9.
3. Variation in mood was ‘normal’ so was not seen as a global change in mood. Participants had
underscored responses in the hope that their symptoms would improve or did not want to admit how
they were feeling. Participants sometimes omit items on suicidality to avoid possible intervention.
4. Some participants observed that they found it difficult to recall what they were doing or how they were
feeling from one day to the next.
Limitations
This was a relatively small sample and it is not possible to infer how common the reasons for disagreement
might be in a more representative sample. The MCID estimate was based on preliminary results.
Inter-relation with other parts of the programme
This study helps to further understand some of the limitations of the PHQ-9 in assessing change. It supports
the view that the PHQ-9 should not be used alone to assess improvement in individuals. Such self-administered
scales need to be supplemented with further clinical assessment. Further clinical assessment is needed if the
PHQ-9 is to be used in clinical practice. This study supported the validity of the GRC, but some respondents
found the retrospective recall required by the question was difficult.
PHASE 2: THE PANDA COHORT STUDY – USING BOTH QUANTITATIVE AND QUALITATIVE METHODS
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Study 2: changes in self-administered measures of depression severity and patients’
own perceptions of changes in their mood – a prospective cohort study
Research aims
The aim was to examine the extent to which changes in scores from self-administered depression
questionnaires (PHQ-9 and BDI-II) disagree with patients’ own self-rated improvement in mood,
and investigate factors that influence this relationship.
Methods of data collection
We used data on the BDI-II and the PHQ-9 and the GRC completed by the PANDA cohort participants at
baseline and at the 2-, 4- and 6-week follow-ups.
Analysis
The change scores for the BDI-II and the PHQ-9 at the 2-, 4- and 6-week follow-ups were calculated by
subtraction from the previous time point. We used a MCID of 20% to create categories of meaningful
improvement, no change and deterioration that could be compared with the GRC. We used logistic
regression models to test whether or not anxiety symptoms, mental and physical health-related quality
of life, negative life events, and social support influenced response to the GRC after adjustment for the
change scores on the BDI-II or the PHQ-9.
Key findings
About half of the patients exhibited disagreement between their response on the GRC and the categories
of meaningful change that we calculated. For the PHQ-9 we found that 51% (95% CI 46% to 55%)
showed disagreement and for the BDI-II we found that 55% (95% CI 51% to 60%) showed disagreement.
We also found that patients with more severe anxiety symptoms were less likely to report feeling better
on the GRC, having taking account of the change in depressive symptoms. Patients with a better mental
health-related quality of life were more likely to report feeling better in a similar analysis. Thus, anxiety and
health-related quality of life contribute to the perception of improvement over and above any change in
depressive symptoms.
Limitations
The PANDA cohort had a low response rate that might have introduced a selection bias. However, as our
selection of patients did not depend on any of the exposure variables, it is unlikely to have biased the
associations we have reported.
Inter-relation with other parts of the programme
The results of this quantitative study supported our finding from the qualitative PANDA studies that
clinicians working in primary care and other clinical settings should be cautious in interpreting changes
in questionnaire scores without further clinical assessment. The study indicated areas where depressive
symptoms questionnaires are not assessing aspects of mental health important to patients. In a RCT,
any variation between individuals should not affect the comparison as the randomisation should lead to
comparable groups.
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Phase 3: the PANDA randomised
controlled trial
Research aims
The aim of the RCT was to investigate the severity and duration of depressive symptoms that are
associated with a clinically important response to sertraline and cost-effectiveness (compared with placebo)
in people with depression who present to primary care. The main hypothesis was that response to
antidepressants would increase with both severity and duration of depressive symptoms. Our primary
analysis was a comparison between sertraline and placebo at 6 weeks.
Methods for data collection
We used broad and pragmatic inclusion criteria, recruiting people who had sought treatment for
depressive symptoms of any severity or duration in primary care. The key entry criterion was that GPs
and/or patients were uncertain about the potential benefits of an antidepressant and we did not set any
severity or duration thresholds as exclusions. Patients were recruited from primary care surgeries in four UK
sites (i.e. Bristol, London, Liverpool and York) and identified by GPs, who either invited patients during a
consultation or conducted a database search and then sent an invitation in the post. Participants were
randomised to 100 mg of sertraline or an identical placebo and followed up at 2, 6 and 12 weeks.
Figure 3 is a flow diagram of the progress through the trial.
Analysis
The primary outcome was the PHQ-9 at the 6-week follow-up. Interactions terms of a realistic size, that
are smaller than the main effect, require very large sample sizes for adequate power. As a result, we
modelled the treatment effect on log-transformed PHQ-9 scores (continuous outcome) using an intention-
to-treat analysis. The exponentiated regression coefficient is the proportional (or percentage) change in
PHQ-9 scores between randomised groups. Evidence of a treatment effect using a proportional model
implies that the treatment effect expressed as a mean difference would increase with severity. In sensitivity
analyses we fitted an additive model using absolute depression scores (non-logged PHQ-9) and calculated
an interaction between treatment allocation and baseline CIS-R depression severity score. However, we
expected the power of this analysis to be low.
Secondary outcomes at 2, 6 and 12 weeks were depressive symptoms and remission assessed using the
PHQ-9 and the BDI-II, generalised anxiety disorder symptoms, mental and physical health-related quality
of life and self-reported global improvement. We used linear multilevel models for repeated measures of
continuous secondary outcomes at 2, 6 and 12 weeks (PHQ-9, BDI-II, GAD-7 and Short Form questionnaire-12
items physical and mental health-related quality of life). Logistic multilevel models were calculated for repeated
measures of binary secondary outcomes at 2, 6, and 12 weeks (remission on the PHQ-9, the BDI-II and
feeling better on the GRC scale).
We undertook a cost-effectiveness analysis from the perspective of the NHS and Personal and Social
Services alongside the PANDA RCT. Quality-of-life data were collected at baseline and 2, 6 and 12 weeks
post randomisation using EQ-5D-5L, from which we calculated QALYs. Costs were collected using patient
records and from resource use questionnaires administered at each follow-up interval. Differences in mean
costs and mean QALYs and net monetary benefits were estimated. Our primary analysis used net monetary
benefit regressions to identify any interaction between the cost-effectiveness of sertraline and subgroups
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Identified as potentially eligible
via record search
(n = 35,719)
Sent an invitation letter
(n = 31,645)
• ‘Yes’ replies, n = 1029
• ‘No’ replies, n = 3399
• No response, n = 27,217
GP suitability checks
(n = 1029)
Patients referred to
study at consultation
(n = 427)
Eligibility checks
(n = 1320; 893 identified via mail outs and 427 via referral)
Proceeded to consenting and randomisation
(n = 671)
Baseline assessment
(n = 667)
Sample for analysis
(n = 653)
• Did not complete PHQ-9, n = 1
Sertraline
(n = 324)
2-week follow-up
(n = 292)
6-week follow-up
(n = 285)
12-week follow-up
(n = 265)
Withdrew
(n = 29)
Withdrew
(n = 14)
Withdrew
(n = 18)
Withdrew
(n = 18)
Withdrew
(n = 7)
Withdrew
(n = 33)
2-week follow-up
(n = 279)
• Not interested, n = 22
• No time, n = 7
• Did not want to take drug,
   n = 2
• Lost to follow-up, n = 2
• Not interested, n = 11
• No time, n = 6
• Lost to follow-up, n = 1
• Not interested, n = 4
• No time, n = 3
• Not interested, n = 7
• No time, n = 3
• Did not want to take drug,
   n = 3
• Lost to follow-up, n = 1
• Not interested, n = 15
• No time, n = 2
• Did not want to take drug,
    n = 1
12-week follow-up
(n = 264)
6-week follow-up
(n = 267)
Placebo
(n = 329)
• Did not complete PHQ-9, n = 1
• 4074 removed from initial list by GPs
• Suitable, n = 893
• Not suitable, n = 110
• GP suitability confirmations not received, n = 20
• Did not proceed to GP screen, n = 6
• Eligible, n = 671
• Not eligible, n = 113
• Declined to take part, n = 376
• Could not be reached to do telephone screening, n = 160
• Consented and completed baseline, n = 667
• Refused to consent, n = 4
• Refused randomisation, n = 12
• Randomised, n = 655
   • Did not complete substantial
      proportion of assessment
      (excluded from analysis), n = 2
• Completed PHQ-9, n = 292
• Missed this follow-up, n = 8
• Not interested, n = 22
• No time, n = 4
• Did not want to take drug,
   n = 1
• Lost to follow up, n = 2
• Completed PHQ-9, n = 277
• Did not complete PHQ-9,
   n = 2
• Missed this follow-up,
   n = 12
• Completed PHQ-9, n = 285
• Missed this follow-up, n = 1
• Completed PHQ-9, n = 267
• Missed this follow-up, n = 6
• Completed PHQ-9, n = 263
• Did not complete PHQ-9,
   n = 2
• Missed this follow-up, n = 3
• Completed PHQ-9, n = 262
• Did not complete PHQ-9,
   n = 2
• Missed this follow-up, n = 2
FIGURE 3 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram: PANDA RCT.
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defined by baseline symptom severity (0 to 11; 12 to 19; ≥ 20 on the CIS-R) and, separately, duration of
symptoms (greater or less than 2 years’ duration). A secondary analysis estimated the cost-effectiveness
of sertraline versus placebo. In sensitivity analyses, we (1) performed a complete-case analysis to check
the robustness of our findings to missing data, (2) examined the impact of excluding costs that were not
judged to be directly related to the treatment of depression and (3) excluded all secondary care costs from
total NHS and Personal and Social Services costs to assess whether or not our findings were robust to
infrequent but expensive hospitalisations.
Key findings
We found no evidence that the antidepressant sertraline reduced depressive symptoms at 6 weeks. In the
sertraline group, PHQ-9 scores were 5% (95% CI –7% to 15%; p = 0.41) lower than those in the placebo
group. In the sensitivity analyses using additive models, there was no evidence of an interaction with
severity or duration of depressive symptoms with treatment effect, but these analyses would have lacked
statistical power.
Of the secondary outcomes, there was strong evidence that sertraline reduced anxiety symptoms (GAD-7
score reduced by 17%, 95% CI 9% to 25%; p < 0.000046) and improved mental but not physical health-
related quality of life as well as self-reported global improvement. There was weak evidence that depressive
symptoms were reduced by sertraline at 12 weeks for both the PHQ-9 and the BDI-II. Given our findings,
we also investigated whether or not the treatment effect for anxiety symptoms was influenced by baseline
severity. We found no evidence that the effect of sertraline on anxiety symptoms varied according to the
severity of anxiety or depressive symptoms. The number needed to treat in order to feel better according to
our self-reported global improvement question was 8.5 (95% CI 5.2 to 22.1) people at 6 weeks and 6.4
(95% CI 4.6 to 10.3) people at 12 weeks.
There was no evidence of an association between the baseline severity of depressive symptoms and the
cost-effectiveness of sertraline. Compared with patients with low symptom severity, the expected net
benefits in patients with moderate symptoms were £64 (95% CI –£312 to £441) and the expected net
benefits in patients with high symptom severity were –£51 (95% CI –£389 to £287). Patients who had a
longer history of depressive symptoms at baseline had lower expected net benefits from sertraline than
those with a shorter history; however, the difference was uncertain (–£132, 95% CI –£431 to £167). In
the secondary analysis, patients treated with sertraline had higher expected net benefits (£118.37, 95% CI
–£23.39 to £260.14) than those in the placebo group. Sertraline had a high probability (> 90%) of being
cost-effective if the health system was willing to pay at least £20,000 per QALY gained.
Limitations
We had broad inclusion criteria and some participants had very few symptoms. This may have reduced the
treatment effect, but our methods of analysis using a proportional approach should have helped to take
account of this. There was attrition of nearly 20% by 12 weeks, although this did not differ by study arm,
and when we investigated the impact of missing data, this did not appear to explain the findings. We had
limited statistical power to explore interactions between treatment response and symptom severity or duration.
It is possible that subgroups in which sertraline was more cost-effective might have become more evident
with a larger sample size or longer follow-up.
Inter-relation with other parts of the programme
The RCT did not find evidence of an early antidepressant effect of sertraline on depressive symptoms in
the population studied. There was, however, evidence that sertraline reduced anxiety symptoms and was
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more likely to lead to a clinically important benefit. The results of the trial and those from the MCID can
be used to provide some initial guidance about the likely cost-effectiveness of sertraline and other SSRI
antidepressants in primary care.
Conclusion
We chose the PHQ-9 as our primary outcome in the PANDA trial. The PHQ-9 is widely used in primary care
and there is evidence that it is better at detecting changes in depressive symptoms after treatment than
other measures.37,55 It also avoids the observer bias that affects clinician-rated HAMD and MADRS scores.
However, our qualitative research identified a number of reasons for disagreement between the PHQ-9
and the self-reported GRC, as well as indicating that up to 50% of patients might show disagreement
between self-reported change and the results of questionnaires. Our findings indicate that the processes
and motivations behind completing the PHQ-9 are complex and influenced by ongoing physical, social
and emotional issues. Our findings suggest that PHQ-9 and, by implication, other self-administered
questionnaires should not be used alone to assess improvement or deterioration. Their use should be
supplemented with further clinical assessment and the use of more open-ended questions.
The MCID is the smallest change in symptoms that is considered clinically worthwhile by the patient. Our
MCID research in phases 1 and 2 has enabled us to develop appropriate analytical methods for estimating
the MCID and to provide values for the MCID in a primary care population for the first time. We can apply
our MCID estimates to the results of the PANDA trial, but we acknowledge that our estimates of MCID are
still uncertain.
When we initially formulated our research questions we assumed that the treatment effect varied
according to depression severity but that the MCID was a fixed value, irrespective of depression severity.
Our results, if anything, now point in the opposite direction, at least when we estimate treatment effects
and MCID using a proportional approach. Our results suggest that sertraline has a similar (proportional)
effect size over the whole range of depression (and anxiety) severity and it is the MCID that changes and
gets larger, proportionally, at lower levels of severity. We have found that, at higher levels of severity, the
proportional approach works better for the MCID. The proportional approach also has attractions when
analysing clinical trial data. It avoids the assumption that the same absolute treatment effect is observed
regardless of whether a person scores 5 or 25 on a scale. This seems unlikely and a proportional reduction
approach appears more plausible as well as providing a better statistical fit to the data.
Contrary to our initial hypothesis in the PANDA trial, we found no evidence of a clinically important
effect of sertraline on depressive symptoms. We found a 5% reduction in the sertraline group at 6 weeks,
and this is considerably smaller than the MCID estimates for the PHQ-9 we have obtained. We cannot
exclude the possibility that sertraline led to a clinically important improvement at 12 weeks, as we found a
13% (95% CI 3% to 21%) reduction in PHQ-9, but this is still well below our MCID. In contrast we
found strong evidence that sertraline reduced anxiety symptoms on the GAD-7, with a reduction of 21%
(95% CI 11% to 30%) at 6 weeks. This is consistent with some of our estimates of the MCID for GAD-7
(see Appendix 4) and suggests that this change is clinically important. We found insufficient evidence of an
interaction between the cost-effectiveness of sertraline and severity or symptom duration that GPs could
use to efficiently target prescribing. There was no evidence of a substantial treatment effect of sertraline
on quality of life, as measured by the EQ-5D-5L. However, sertraline is an inexpensive intervention that
has a high probability of being cost-effective compared with placebo across primary care patients with
depression or low mood.
Our MCID estimates are based on an average within-person change related to improvement; however,
a RCT compares groups. Application of our results has therefore required a counterfactual argument in
which researchers compare the same individual(s) who receive placebo but who might have received
the active treatment. The MCID estimated from a within-person calculation can then be applied to the
between-group differences in a clinical trial.
PHASE 3: THE PANDA RANDOMISED CONTROLLED TRIAL
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Our estimates of MCID could be used to guide decisions about whether or not a treatment will benefit an
individual. For this, one needs to be able to predict the likely score for that person on the proposed
outcome measure were they not to receive that treatment. In other words, we need to know the likely
value of an individual’s PHQ-9 or GAD-7 score at follow-up, 6 or 12 weeks later, if they were to receive a
placebo. The expected value of the placebo at follow-up can then be used to determine the appropriate
initial value for the MCID and thus decide if the proportional reduction expected from a treatment would
be larger than the MCID for such a person. For this to be feasible, we would need more precise estimates
of MCID and also the ability to predict future scores of patients on the basis of their clinical and other
characteristics.
Finally, we can make some very approximate estimate of what proportion of participants in the PANDA cohort
would probably have benefited from treatment. From our results in Appendix 4, it is clear that those with a
GAD-7 score of 3 at 6 weeks have a MCID of about 50%. It is highly unlikely that those individuals would have
experienced any benefit from sertraline. In the PANDA RCT, about 30% of participants scored ≤ 3 at 6 weeks.
However, we cannot conclude this with any confidence at this stage. We do not know the distribution of
symptoms in those receiving antidepressants in the UK and our estimates of MCID are approximate. Our overall
results are reassuring in indicating that, on average, patients in the PANDA RCT are benefiting from sertraline.
However, it is probable that a substantial proportion or patients receiving antidepressants are not experiencing
any individual benefit. For clinicians to be confident about recommending treatment to patients, we need
accurate information on individualised treatment effects and the outcome without treatment as well as MCID.
Of course, any recommendations for treatment will also have to take account of any risks and adverse effects
that result from the treatment as well as patient preference.
Recommendations for future research
Our finding that sertraline seems to be effective for anxiety but not depressive symptoms has a potential
implication for understanding the mechanisms of antidepressant treatment as well as the clinical benefit
that patient’s will experience.
Research recommendation 1
Future research into the mechanism of action of antidepressants should examine the biology of
anxiety symptoms.
The result of the RCT also questions the reliance of current clinical guidelines on existing placebo-controlled
studies that have been conducted largely for regulatory purposes. Cipriani et al.’s review28 highlights the
poor quality of the existing research. Antidepressants are commonly used medications and it is concerning
that we still have a number of outstanding questions about their efficacy and clinical indication many years
after they were introduced. The use of behavioural tasks such as face recognition and memory for words
might be a useful way to investigate these mechanistic aspects.
Research recommendation 2
Future studies should investigate the clinical effectiveness of antidepressants for anxiety disorders in UK
primary care population.
We would recommend that future investigation of antidepressant efficacy should have longer follow-ups
to see if there are longer-term benefits for depressive symptoms as well as anxiety symptoms. We would
encourage use of more detailed outcome measures, using self-reported information, to ensure that the
whole range of symptoms that are common in depression and anxiety are studied. The use of self-reported
improvement (GRC) seems a valuable outcome measure in clinical trials.
Research recommendation 3
Further investigation of minimal clinically important differences.
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Further research is needed to investigate the size of the MCID and the factors that might influence whether
or not patients report improvement. We need more precise estimates to guide decision-making. We have
provided evidence that patients’ reporting of feeling better can be affected by various other factors, such as
anxiety and physical changes. Further investigation of this will also help inform how MCIDs could be used
clinically to provide treatment recommendations.
Implications for practice and any lessons learned
The PHQ-9 and similar self-administered questionnaires should not be used alone in assessing improvement
or deterioration. It is important to supplement such standardised measures with a clinical assessment.
Sertraline is effective and cost-effective in reducing anxiety symptoms such as worry and restlessness in the
first 6 weeks of treatment in people who present with depressive symptoms. Any effect on depressive
symptoms takes longer to emerge; although an improvement in anxious symptoms in someone presenting
with depressive symptoms could lead to a clinical benefit. Patients who present to primary care with
depressive symptoms have a wide range of severity of symptoms. Overall, this population is likely to benefit
from SSRI antidepressants. Our findings support the prescription of SSRI antidepressants in a wider group of
participants than previously thought, including those who do not meet diagnostic criteria for depression or
generalised anxiety disorder, especially when anxiety symptoms such as worry and restlessness are present.
Patient and public involvement
Paul Lanham, a service user and a co-applicant, was also a member of the independent steering committee
during phase 3 of the programme and was involved in PANDA for over 6 years. Paul Lanham and Derek Riozzie
have also contributed to PANDA annual meetings where all co-applicants and researchers discuss progress,
review the protocols and discuss any findings. They made important contributions to the discussion and
influenced the interpretation of the results and decisions about study design. All study documentations have
been revised and commented on by Paul, Derek and the user group co-ordinated by Derek at Liverpool
University. In addition, we enlisted the support of the North London Service Users Research Forum (SURF).
The SURF was co-founded in 2007 by service users and clinical academic psychiatrists at University College
London to provide meaningful consultation on research. It has 12 members with mental health problems.
Since 2007, it has consulted on > 50 projects and SURF members have been invited to join steering/
management groups on many of these. As a result, the group is very experienced and confident about
the advice and input they provide; their comments on the trial paperwork have been invaluable. The letter
templates, patient information sheets and the questionnaire were amended to reflect the patient and public
involvement (PPI) feedback. We also consulted on the protocol concerning self-harm or risk of self-harm,
which we used if patients reported this in the course of the cohort and RCT. Having close involvement of
the PPI for the duration of the programme (i.e. over 6 years) has been invaluable for its success. It has also
enabled us to build on it and we have recruited a PANDA RCT participant to represent PPI on a different
depression trial: ANTidepressants to prevent reLapse in dEpRession (ANTLER).64 We plan to carry on using
the services users’ comments in the design, documentation and analysis of any future studies.
PHASE 3: THE PANDA RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Acknowledgements
We are grateful to all the patients who took part in the PANDA studies. We would like to thank theGPs and GP surgery staff who supported recruitment for this research. We have been supported by
the following Clinical Research Networks (CRNs): North Thames CRN, CRN North West London, CRN South
London, North West Coast CRN, Greater Manchester CRN, West Midlands CRN, West of England CRN,
Yorkshire and Humber CRN and North East and Cumbria CRN.
We would like to acknowledge the particular input of the CRN research nurses and CSOs: Dawn Adams,
Heather Tinker, Lynsey Wilson, Tara Harvey, Khatiba Raja, Zara Prem, Beena Bauluck, Yvonne Foreshaw,
Cynthia Sajani, Jahnese Maya, Anna Townsend-Rose, Emily Clare, Rachel Nixon, Pam Clark and Irene Sambath.
We would also like to acknowledge Vivien Jones for providing administrative support at the Bristol site;
Rebecca Rawlinson at the Liverpool site; Bryony Thomson and Yvonne Donkor at University College London;
and Wendy Cattle at York. Jodi Prem was instrumental in recruitment at York.
We also thank Carolyn Chew-Graham, Ian Anderson, Anne Rogers, Evan Kontopantelis, Paul Lanham,
Christopher Williams, Richard Bying and Obi Ukoumunne for generously agreeing to sit on the Trial
Steering Committee and Data Monitoring Committee.
Ethics approval and sponsorships
For the PANDA cohort study, ethics approval was obtained from National Research Ethics Service (NRES)
Committee South West-Central Bristol. The University of Bristol acted as sponsor for the study.
The PANDA RCT was approved by NRES Committee East of England – Cambridge South (reference number
13/EE/0418). The Joint Research Office, University College London acted as sponsor for the RCT.
Contributions of authors
Larisa Duffy was the programme manager and with Gemma Lewis was responsible for drafting the
report.
Larisa Duffy, Gemma Lewis, Anthony Ades, Ricardo Araya, Jessica Bone, Sally Brabyn,
Katherine Button, Rachel Churchill, Tim Croudace, Catherine Derrick, Padraig Dixon,
Christopher Dowrick, Christopher Fawsitt, Louise Fusco, Simon Gilbody, Catherine Harmer,
Catherine Hobbs, William Hollingworth, Vivien Jones, Tony Kendrick, David Kessler, Naila Khan,
Daphne Kounali, Paul Lanham, Alice Malpass, Marcus Munafo, Jodi Pervin, Tim Peters,
Derek Riozzie, Jude Robinson, George Salaminios, Debbie Sharp, Howard Thom, Laura Thomas,
Nicky Welton, Nicola Wiles, Rebecca Woodhouse and Glyn Lewis contributed to the constituent
papers in the appendices. The papers included as appendices each have its own lists of authors.
Anthony Ades, Ricardo Araya, Rachel Churchill, Tim Croudace, Christopher Dowrick, Simon Gilbody,
William Hollingworth, Tony Kendrick, David Kessler, Paul Lanham, Alice Malpass, Tim Peters,
Jude Robinson, Debbie Sharp, Nicky Welton, Nicola Wiles and Glyn Lewis were responsible for the
original proposal and for securing funding.
Glyn Lewis was chief investigator of the programme and had clinical responsibly for the RCT recruitment
at the London site.
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
All authors have provided substantial contributions to the conception and design of the PANDA
programme and interpretation of data and had input into drafting the report and/or revising it critically for
important intellectual content. All authors have given final approval of the version to be published.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
References
1. World Health Organization. Depression: Key Facts. 2018. URL: www.who.int/news-room/fact-sheets/
detail/depression (accessed 15 August 2019).
2. NHS Digital. Prescription Cost Analysis – England, 2018 [PAS]. URL: https://digital.nhs.uk/data-and-
information/publications/statistical/prescription-cost-analysis/2018 (accessed 15 August 2019).
3. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
https://doi.org/10.1136/jnnp.23.1.56
4. National Institute for Health and Care Excellence. Depression: Management of Depression in
Primary and Secondary Care. Clinical Guideline 23. London: NICE; 2004.
5. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in
psychotherapy research. J Consult Clin Psychol 1991;59:12–19. https://doi.org/10.1037/
0022-006X.59.1.12
6. McMillan D, Gilbody S, Richards D. Defining successful treatment outcome in depression using the
PHQ-9: a comparison of methods. J Affect Disord 2010;127:122–9. https://doi.org/10.1016/
j.jad.2010.04.030
7. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically
important difference. Control Clin Trials 1989;10:407–15. https://doi.org/10.1016/0197-2456(89)
90005-6
8. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the
Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007;22:1596–602.
https://doi.org/10.1007/s11606-007-0333-y
9. National Collaborating Centre for Mental Health. Depression: The Treatment and Management of
Depression in Adults (Updated Edition). Leicester and London: The British Psychological Society and
The Royal College of Psychiatrists; 2010.
10. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment
outcomes with the patient health questionnaire-9. Med Care 2004;42:1194–201. https://doi.org/
10.1097/00005650-200412000-00006
11. Jacobson N, Greenley D. What is recovery? A conceptual model and explication. Psychiatr Serv
2001;52:482–5. https://doi.org/10.1176/appi.ps.52.4.482
12. Ridge D, Ziebland S. ‘The old me could never have done that’: how people give meaning to
recovery following depression. Qual Heal Res 2006;16:1038–53. https://doi.org/10.1177/
1049732306292132
13. Malpass A, Shaw A, Kessler D, Sharp D. Concordance between PHQ-9 scores and patients’
experiences of depression: a mixed methods study. Br J Gen Pract 2010;60:e231–8. https://doi.org/
10.3399/bjgp10X502119
14. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive
neuropsychological model of antidepressant drug action. Br J Psychiatry 2009;195:102–8.
https://doi.org/10.1192/bjp.bp.108.051193
15. Beck TA, Ruch J, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press;
1987.
16. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX:
Psychological Corporation; 1996.
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
17. Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand
1983;67:361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
18. Cameron IM, Crawford JR, Lawton K, Reid IC. Psychometric comparison of PHQ-9 and HADS
for measuring depression severity in primary care. Br J Gen Pract 2008;58:32–6. https://doi.org/
10.3399/bjgp08X263794
19. National Institute for Health and Care Excellence. Management of Depression in Primary and
Secondary Care. Clinical Guidelines 23. London: NICE; 2010.
20. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and
antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.
PLOS Med 2008;5:e45. https://doi.org/10.1371/journal.pmed.0050045
21. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to
antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin
Psychopharmacol 2002;22:40–5. https://doi.org/10.1097/00004714-200202000-00007
22. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J.
Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA
2010;303:47–53. https://doi.org/10.1001/jama.2009.1943
23. Gibbons RD, Hur K, Hendricks Brown C, Davis JM, Mann JJ. Who benefits from antidepressants?
Synthesis of 6-week patient-level outcomes from double-blind placebo controlled randomized trials
of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572–9. https://doi.org/10.1001/
archgenpsychiatry.2011.2044
24. Rabinowitz J, Werbeloff N, Mandel FS, Menard F, Marangell L, Kapur S. Initial depression severity
and response to antidepressants v. placebo: patient-level data analysis from 34 randomised
controlled trials. Br J Psychiatry 2016;209:427–8. https://doi.org/10.1192/bjp.bp.115.173906
25. Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, et al. Initial severity of major
depression and efficacy of new generation antidepressants: individual participant data meta-analysis.
Acta Psychiatr Scand 2018;137:450–8. https://doi.org/10.1111/acps.12886
26. Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M. Efficacy of antidepressants and
benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry
2011;198:11–16, sup 1. https://doi.org/10.1192/bjp.bp.109.076448
27. Zimmerman M, Posternak MA, Chelminski I. Symptom severity and exclusion from antidepressant
efficacy trials. J Clin Psychopharmacol 2002;22:610–14. https://doi.org/10.1097/00004714-
200212000-00011
28. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative
efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major
depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357–66.
https://doi.org/10.1016/S0140-6736(17)32802-7
29. World Health Organization. Classification of Mental and Behavioural Disorders. Geneva: World
Health Organization; 1992.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV.
4th edn. Washington, D.C.: American Psychiatric Association Publishing; 1994.
31. Rai D, Skapinakis P, Wiles N, Lewis G, Araya R. Common mental disorders, subthreshold symptoms
and disability: longitudinal study. Br J Psychiatry 2010;197:411–12. https://doi.org/
10.1192/bjp.bp.110.079244
32. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from
work in a prospective epidemiologic survey. JAMA 1990;264:2524–8. https://doi.org/10.1001/
jama.1990.03450190056028
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
33. de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review
and meta-analysis. Psychol Med 1999;29:1273–89. https://doi.org/10.1017/S0033291799001324
34. de Lima MS, Moncrieffe JA. Review: antidepressant drugs are effective in dysthymia. Evid Based
Ment Health 1998;1:111. https://doi.org/10.1136/ebmh.1.4.111
35. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with
antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.
J Psychopharmacol 2000;14:3–20. https://doi.org/10.1177/026988110001400101
36. Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, et al. Minimal clinically important
difference on the Beck Depression Inventory–II according to the patient’s perspective. Psychol Med
England 2015;45:3269–79. https://doi.org/10.1017/S0033291715001270
37. Kounali DZ, Button KS, Lewis G, Ades AE. The relative responsiveness of test instruments can
be estimated using a meta-analytic approach: an illustration with treatments for depression.
J Clin Epidemiol 2016;77:68–77. https://doi.org/10.1016/j.jclinepi.2016.03.005
38. Thom H, Jackson C, Welton N, Sharples L. Using parameter constraints to choose state structures
in cost-effectiveness modelling. PharmacoEconomics 2017;35:951–62. https://doi.org/10.1007/
s40273-017-0501-9
39. Malpass A, Dowrick C, Gilbody S, Robinson J, Wiles N, Duffy L, Lewis G. Usefulness of PHQ-9 in
primary care to determine meaningful symptoms of low mood: a qualitative study. Br J Gen Pract
2016;66:e78–84. https://doi.org/10.3399/bjgp16X683473
40. Bone JK, Lewis G, Button KS, Duffy L, Harmer CJ, Munafò MR, et al. Variation in recognition of
happy and sad facial expressions and self-reported depressive symptom severity: a prospective
cohort study. J Affect Disord 2019;257:461–9. https://doi.org/10.1016/j.jad.2019.06.025
41. Lewis G, Kounali DZ, Button KS, Duffy L, Wiles NJ, Munafò MR, et al. Variation in the recall of
socially rewarding information and depressive symptom severity: a prospective cohort study.
Acta Psychiatr Scand 2017;135:489–98. https://doi.org/10.1111/acps.12729
42. Robinson J, Khan N, Fusco L, Malpass A, Lewis G, Dowrick C. Why are there discrepancies
between depressed patients’ Global Rating of Change and scores on the Patient Health
Questionnaire depression module? A qualitative study of primary care in England. BMJ Open
2017;7:e014519. https://doi.org/10.1136/bmjopen-2016-014519
43. Salaminios G, Duffy L, Ades A, Araya R, Button KS, Churchill R, et al. A randomised controlled trial
assessing the severity and duration of depressive symptoms associated with a clinically significant
response to sertraline versus placebo, in people presenting to primary care with depression
(PANDA trial): study protocol for a randomised controlled trial. Trials 2017;18:496. https://doi.org/
10.1186/s13063-017-2253-4
44. Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, et al. The clinical effectiveness of sertraline
in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-
blind, placebo-controlled randomised trial [published online ahead of print September 19 2019].
Lancet 2019. https://doi.org/10.1016/S2215-0366(19)30366-9
45. Hollingworth W, Fawsitt CG, Dixon P, Duffy L, Araya R, Peters TJ, et al. Cost-effectiveness of
sertraline in primary care according to initial severity and duration of depressive symptoms: findings
from the PANDA RCT [published online ahead of print November 27 2019]. PharmacoEconomics
Open 2019. https://doi.org/10.1007/s41669-019-00188-5
46. Lewis GH. PANDA Analysis Plan. London: Division of Psychiatry, University College London; 2017.
URL: http://discovery.ucl.ac.uk/10041458/ (accessed 19 September 2019).
47. Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, et al. GENetic and clinical predictors
of treatment response in depression: the GenPod randomised trial protocol. Trials 2008;9:29.
https://doi.org/10.1186/1745-6215-9-29
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
48. Thomas LJ, Abel A, Ridgway N, Peters T, Kessler D, Hollinghurst S, et al. Cognitive behavioural
therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the
CoBalT randomised controlled trial protocol. Contemp Clin Trials 2012;33:312–19. https://doi.org/
10.1016/j.cct.2011.10.016
49. Baxter H, Winder R, Chalder M, Wright C, Sherlock S, Haase A, et al. Physical activity as a treatment
for depression: the TREAD randomised trial protocol. Trials 2010;11:105. https://doi.org/10.1186/
1745-6215-11-105
50. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol
1967;6:278–96. https://doi.org/10.1111/j.2044-8260.1967.tb00530.x
51. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J
Psychiatry 1979;134:382–9. https://doi.org/10.1192/bjp.134.4.382
52. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. https://doi.org/10.1016/
0168-8510(96)00822-6
53. Stewart AD, Hays RD, Ware JE. The MOS short-form General Health Survey. Med Care
1988;26:724–32. https://doi.org/10.1097/00005650-198807000-00007
54. Lu G, Kounali D, Ades AE. Simultaneous multioutcome synthesis and mapping of treatment effects
to a common scale. Value Health 2014;17:280–7. https://doi.org/10.1016/j.jval.2013.12.006
55. Titov N, Dear BF, McMillan D, Anderson T, Zou J, Sunderland M. Psychometric comparison of the
PHQ-9 and BDI-II for measuring response during treatment of depression. Cogn Behav Ther
2011;40:126–36. https://doi.org/10.1080/16506073.2010.550059
56. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy
and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Lancet 2009;373:746–58. https://doi.org/10.1016/S0140-6736(09)60046-5
57. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS Book: A Practical Introduction to
Bayesian Analysis. Boca Raton, FL: CRC Press, 2013.
58. Briggs AH, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford:
Oxford University Press; 2006.
59. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in
Healthcare. Hoboken, NJ: John Wiley & Sons; 2012. https://doi.org/10.1002/9781119942986
60. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision
modeling.Med Decis Making 2004;24:207–27. https://doi.org/10.1177/0272989X04263162
61. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized
assessment for use by lay interviewers. Psychol Med 1992;22:465–86. https://doi.org/10.1017/
S0033291700030415
62. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In Huberman AM, Miles MB,
editors. The Qualitative Researcher’s Companion. Thousand Oaks, CA: Sage Publications, Inc.; 2002.
pp. 305–29.
63. Willis GB. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA:
Sage Publications, Inc.; 2005.
64. Duffy L, Bacon F, Clarke CS, Donkor Y, Freemantle N, Gilbody S, et al. A randomised controlled
trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in
primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants
to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials 2019;20:319.
https://doi.org/10.1186/s13063-019-3390-8
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Appendix 1 Minimal clinically important difference
on the Beck Depression Inventory, version 2, according
to the patient’s perspective
See Button et al.36
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Appendix 2 The relative responsiveness of test
instruments can be estimated using a meta-analytic
approach: an illustration with treatments for depression
See Kounali et al.37
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Appendix 3 Using parameter constraints to
choose state structures in cost-effectiveness modelling
See Thom et al.38
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Appendix 4 How much change is enough?
Evidence from a longitudinal study on depression in
UK primary care
How much change is enough? Evidence from a longitudinal study on depression in UK
primary care.
Background 
The Patient Health Questionnaire (PHQ9), the Beck Depression Inventory, 2nd edition 
(BDI-II) and the Generalised Anxiety Disorder Assessment (GAD-7) are widely used in the 
evaluation of interventions for depression and anxiety. Little empirical study of the Minimum 
Clinically Important Difference (MCID) exists for these scales.
Method
A prospective cohort of 400 patients in primary care, UK, were interviewed on four occasions,
two weeks apart. At each time point, participants completed all three questionnaires and a 
‘global rating of change’ scale (GRS). MCID estimation relied on the reduction in scores in
those reporting improvement on the GRS scale. The data was modelled using a Bayesian
hierarchical beta-regression stratified by three categories of baseline severity. This method
also allowed us to calculate receiver operating characteristics (ROC) parameters. 
Results 
For moderate severity, those who reported improvement had a change of 21% (95%
confidence interval (CI) -26.7-14.9) on the PHQ9; 23% (95% CI -27.8 -18.0) on the BDI-II 
and 26.8% (95% CI -33.5 -20.1) on the GAD-7. Using ROC analysis, the threshold score
below which participants were more likely to report improvement than no change were -1.7, 
-3.5 and -1.5 points on the PHQ9, BDI-II and GAD-7, respectively at moderate severity. This
corresponds to 21%, 24% and 27% reduction. At the lowest severity the threshold score 
rose markedly as a percentage, indicating the difficulty in discriminating change at low 
severity levels. 
Conclusions 
The self-administered scales had similar characteristics in relation to self-reported
improvement. An MCID of about a 20% reduction in scores is a useful rough guide for these 
scales. The MCID increases, as a percentage, for those at lower severity. This indicates that
treatments are unlikely to lead to the experience of benefit in those with low symptoms. 
Keywords: depression, primary care, BDI-II, PHQ-9, GAD-7, minimal clinically important 
difference, baseline severity, beta-regression. 
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Introduction
Depression is a common reason for consultation in primary care (McManus S et al., 2014) 
and a major public health problem. Clinicians are faced with the difficulty of making
treatment recommendations to patients they see in primary care based upon evidence that
used assessments for depressive symptoms that were developed primarily for research
purposes.  Deciding what constitutes a clinically important treatment effect for those 
research assessments is therefore essential for interpreting the results of clinical research 
and designing randomised trials. 
The minimum clinically important difference (MCID) provides a measure of the smallest
change in an outcome that is perceived as important to patients. The UK National Institute 
for Health and Care Excellence (NICE) proposed a reduction of three points on the Hamilton 
Depression Rating Scale as clinically important, but this was based solely on the opinion of
an expert group (Kendrick and Pilling, 2012).  Others have used approaches that rely upon
the error of measurement of scales. (Christensen and Mendoza, 1986, Hays and Hadorn,
1992, Jacobson et al., 1984, Jacobson and Truax, 1991, Kendall PC et al., 1999) but this
approach does not incorporate the patients’ perspective.
Clinicians and policy makers are giving more emphasis to patients’ perspectives in the 
evaluation of interventions and public health policies. It is therefore important to establish an 
MCID anchored in the experiences of patients. In previous work, we have investigated the 
MCID for the Beck Depression Inventory (BDI-II) from the perspective of the patient (Button
et al., 2015). Using a Global Rating of Change Scale (GRS), patients were asked whether 
they felt better, the same, or worse since they were last seen, and the MCID was calculated
as the minimum change in depression scores associated with reporting feeling ‘better’.
This study found that, in absolute terms, the MCID was larger for those with more severe
depressive symptoms at baseline, and therefore concluded that MCID might be best
conceived as a proportional change (Button et al., 2015). This previous study used data 
from clinical trials in which patients were only eligible if they exceeded a severity threshold,
and thus excluded patients with lower depression scores. 
The current study further develops the previous approach. The aim was to estimate the 
MCID for the BDI-II, PHQ9 and GAD-7 scales. It studies a sample of primary care patients
who have been consulting about symptoms of depression and anxiety with broad inclusion
criteria to better reflect the population seeking help. We have also extended the work to
include the PHQ9 and GAD-7 that are frequently used in research and are the primary
outcomes in Improving Access to Psychological Therapies (IAPT) services. The large 
sample size also allowed us to refine GRS groupings that allow comparisons between those 
reporting improvement against those reporting “feeling the same” rather than merging the 
latter group with those “feeling worse”. We report on three different approaches to estimate
the MCID: the mean change for those “feeling better”, the mean difference in change 
between “feeling better” and “feeling the same”, and the threshold value below which 
participants are more likely to report “feeling better” than report “feeling the same”. 
Method
Participants
The sample was recruited from primary care surgeries in three UK sites (Bristol, Liverpool, 
and York) between February 2013 and April 2014. This study was part of the PANDA
programme (NIHR programme “What are the indications for Prescribing ANtiDepressAnts 
that will lead to clinical benefit?”; NIHR Programme Grant= RP PG 0610 10048). One of the 
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primary objectives of this element of the programme was to estimate the MCID for measures 
of depression by assembling a pragmatic and contemporary cohort of patients seeking help 
in primary care with a broad range of depression symptom severity.  As anxiety symptoms 
are often co-morbid with depression and no NICE guidelines address such presentations, 
the study also collected data on a measure of generalised anxiety, the GAD-7, enabling us 
to additionally explore the MCID for such a measure (Kendrick and Pilling, 2012). 
Computerised records at collaborating general practices at each site were searched to
identify people who had reported depressive episodes, depressed mood, depressive
symptoms or a major depressive episode in the past year. Individuals were included if they
were aged between 18 and 74 years, treated or not treated with antidepressants, and
referred or not referred to IAPT services. We excluded people who: were diagnosed with
bipolar disorder, psychosis or an eating disorder; had alcohol or substance use problems; 
were unable to complete study questionnaires; or were 30 weeks or more pregnant.  Overall,
7,721 patients were sent an information letter in the post and 1,470 (19%) replied. Of these,
821 were willing to be contacted, 23 (3%) of whom were ineligible. The remaining 798 were
contacted to arrange an interview, and 563 consented to take part in the cohort study. Data 
on our measures were collected at four time points, each approximately two weeks apart. At
time one, 559 people provided data (4 could not be contacted), with corresponding figures at
follow-ups two, three and four of 476 (85%), 443 (79%) and 430 (77%) respectively. 400
(72%) participants provided data at each of the four follow-ups and were included in our
analyses. Participants missing data at one or more follow-ups were excluded.  
Interviews were conducted at the participant’s home or GP surgery. All participants provided
written informed consent, and ethical approval was obtained from NRES Committee South 
West-Central Bristol. The authors assert that all procedures contributing to this work comply 
with the ethical standards of the relevant national and institutional committees on human 
experimentation and with the Helsinki Declaration of 1975, as revised in 2008. 
Measures
Beck Depression Inventory–II (BDI-II)
The BDI-II (Beck et al., 1996) is a self-report measure of the severity of depressive symptoms,
consisting of 21 items, each assessed using a 4-point scale ranging from 0 to 3. Possible 
scores range from 0 to 63. Higher scores indicate a greater severity of depressive symptoms.
Participants were asked about the previous 2 weeks.
Patient Health Questionnaire (PHQ9)
The PHQ9 (Kroenke and Spitzer, 2002) is a self-report measure of the severity of depressive
symptoms, consisting of 9 items each with a 4-point scale ranging from ‘Not at all’ (0) to 
‘Nearly every day’ (3). Possible scores range from 0 to 27, and higher scores indicate a greater
severity of depressive symptoms. The PHQ9 asked about the previous 2 weeks.
Anxiety
The Generalised Anxiety Disorder Assessment (GAD-7) (Spitzer et al., 2006) was used to
measure anxiety at each time point. The GAD-7 is a self-report measure of generalised
anxiety symptoms consisting of 7 items, each assessed using a 4-point scale ranging from
‘Not at all’ (0) to ‘Nearly every day’ (3). Possible scores range from 0 to 21. Higher scores 
indicate a greater severity of anxiety and questions were asked about the previous 2 weeks.
Global Rating of Change Scale 
The global rating of change scale is a self-report measure of subjective well-being over time, 
asking participants: “Compared to when we last saw you 2 weeks ago how have your moods 
and feelings changed?”. The five possible responses were: ‘I feel a lot better’ (1), ‘I feel 
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slightly better’ (2), ‘I feel about the same’ (3), ‘I feel slightly worse’ (4), ‘I feel a lot worse’ (5).
Participants completed two global rating of change scales (separated by other questionnaires) 
at each time point, to assess reliability (Kamper et al., 2009, Robinson et al., 2017). 
Clinical Interview Schedule – Revised (CIS-R) 
The CIS-R (Lewis and Pelosi, 1990) is a fully structured self-administered computerised
assessment of common mental disorders that has been extensively used in community
samples. Participants were assessed using the CIS-R at baseline only. The thresholds used 
(0-11/12-19/20+) were those pre-specified in the protocol for the subsequent PANDA trial 
(Salaminios et al., 2017). 
Demographics
Demographic variables were measured at baseline using a self-administered computerised
assessment. These were age, sex, ethnicity, employment status, financial status, and 
education level.
Current Antidepressant Use
A short self-report measure was used to assess current medication use at each time point.
Participants were asked whether or not they were currently taking antidepressants. 
Statistical Analyses
Accounting for baseline dependency 
We previously found that MCID on the BDI-II in absolute terms varied according to baseline
severity, with larger MCID estimates at higher levels of severity (Button et al., 2015). In
preliminary analyses in the current study it was also noted that the relationship between the
GRS and severity on the three measures was different for participants with low (<=11),
medium (12-19) and high (>=20) scores on CIS-R completed at time 1. For example, in 
Table 1 the average initial PHQ9 score in the group reporting “feeling the same” is lower 
than in those reporting “feeling better” when baseline severity is low (CIS-R<11). In contrast,
in the high (CIS-R >20) the average initial PHQ9 score was lower in those reporting “feeling
better” compared to those reporting “feeling the same”. These patterns were similar for all 
outcomes (Tables 2 and 3). For this reason, we stratified all future analyses according to the
three severity groupings and this allowed estimation of group-specific average initial values
and differences in change scores across all the time points. Using the CIS-R also conferred 
the advantage of providing a measure of baseline severity independent of the scales of interest.
Reliability of the Global Rating of Change Scale (GRS) 
Reliability of the Global Rating of change scale was quantified using the two repeated
assessments completed by the patient within each period, in both absolute and relative 
terms. Absolute levels of agreement were estimated via the (unweighted) Kappa coefficient
(Landis and Koch., 1977). We also assessed reliability using the intra-class correlation 
coefficient (Skrondal and Rabe-Hesketh., 2004). We carried out the calculations using Stata
version 15 (StataCorp, 2015).
Change in BDI-II, PHQ9 and GAD-7 scores - Modelling 
We used Bayesian hierarchical beta-regression models to estimate the changes (as 
proportions) in symptom scores measured by the three scales (BDI-II and PHQ9 and GAD-7)
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and over multiple waves in each of the GRS groupings and baseline CIS-R score (Verkuilen J 
and M, 2012, Zimprich, 2010).  We carried out comparisons of different models using various
distributional assumptions and link functions, and found the beta-regression to perform best
(Spiegelhalter et al., 2002). We modelled change in symptoms on the proportional scale.  
A detailed description of the model specifics, model estimates are provided in the online 
Appendix 1. We carried out model fitting, model comparisons and post-estimation 
calculations using the WinBUGS statistical software (Spiegelhalter et al., 2007). Through
modelling, we estimated GRS-specific changes over time and potential interactions with the 
baseline CIS-R. Given the small sample sizes in some GRS response options, these were
amalgamated as follows: “I feel a lot better” (1) and “I feel slightly better” (2) under the 
revised category “Feeling better”; “I feel slightly worse” (4) and “I feel a lot worse” (5) under
the revised category: “Feeling worse”.
We express differences in terms of proportional as well as absolute scores using standard
post-estimation calculations. The variability in the distribution of change in the different 
groups was also estimated. The difference in change between the GRS groups in absolute 
as well as standardised form were also calculated post-estimation to assess the ability of the 
different instruments to discriminate between the groups.
Receiver Operating Characteristic (ROC) analysis 
We estimated the threshold value of change that corresponds to the maximum improvement
in sensitivity over chance. Estimation of the sensitivity and specificity corresponding to this
optimum is a function of the ROC parameters under assumptions of approximate normality 
(Details in Appendix 1). 
The Receiver Operator Characteristic (ROC) parameters required for the derivation of the 
MCID were based on post-estimation calculations for functions of the parameters of the 
above regression models. These consist of the standardised difference between the group 
reporting “feeling better” and the group reporting “feeling the same” as well as the ratio of the 
variances between the two groups. It should be noted that in previous work (Button et al., 
2015) the groups reporting “feeling worse” and “feeling the same” were merged whereas in
this work the group reporting “feeling worse” does not contribute any information to the 
estimation of the threshold value of change which optimally discriminates from the group 
reporting improvement.  
Results
Sample Characteristics
Patients with at least one follow-up visit with data on the GRS was needed to estimate
change. 400 patients were included in the analyses and had complete data for all four time
points. No baseline differences between excluded and included patients were apparent in 
the outcomes under study or their demographics. Demographic and clinical characteristics
are shown in Table A2.1 (Appendix 2). Participants were aged 17 to 71 years (mean = 48.7),
and the majority were female, white, married and employed. Roughly a third of participants
had completed higher education. Just under half of participants met ICD-10 criteria for major 
depressive disorder at baseline. The vast majority reported using antidepressants at each
time point.
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Descriptive statistics of the distribution of GRS scale over time overall as well as stratified by
CIS-R are presented in Appendix 2 (Table A2.2, Figure A2.1). There were no significant 
changes in GRS scores over time. 
Test-Retest Reliability of the Global Rating Scale 
Absolute levels of agreement were found to be substantial or excellent, with kappa values 
of 0.73, 0.84, 0.86 and 0.81 for baseline, first, second and third visits respectively. The 
corresponding levels of agreement were 86%, 90%, 91% and 88% for baseline, first, second
and third visits respectively. The intraclass correlation coefficients were: 0.95 (95% CI 0.94, 
0.96) at baseline; 0.98 (0.97, 0.99) at the first visit; 0.92 (0.90, 0.94) at the second; and 0.99
(0.98, 0.994) at the third. 
Change in BDI-II, PHQ9 and GAD-7 over time for each grouping of the Global Rating 
of Change (GRS) scale 
In Table 1 we present estimated mean initial levels and changes in mean scores in both 
absolute and proportional terms for each CIS-R severity group and GRS group on the PHQ9. 
Tables 2 and 3 provide the same estimates for the BDI-II and GAD-7 (see methods for an
explanation of this analytical approach). The initial scores vary depending upon the CIS-R 
groups. The changes required for people to report “feeling better” increase with baseline
severity (Figures 1-3). It is also noteworthy that the increases seen for those “feeling worse”
were not as large as the reductions in those reporting “feeling better”.
No differences in the estimated percentage changes for those reporting “feeling better” was 
found across CIS-R severity groups, for all outcomes (Tables 1-3). In Figures 1-3 we present 
the changes for those reporting “feeling better” and those reporting “feeling the same” for 
each of the outcomes as a function of their initial scores.  
Participants who reported “feeling the same”, also experienced reductions in score on all 
outcomes. In Table 4 we have estimated the difference in the changes reported by those who
report “feeling better” and those who report “feeling the same”, in absolute scores as well as 
a percentage of their respective baseline scores. In general, the differences between “feeling
better” and the same became larger as the CIS-R severity increased. For patients with medium
levels of CIS-R there was no evidence that these difference in reduction were different to the
changes observed for the lower CIS-R category. Only for those with high CIS-R scores at
baseline, the difference in reductions between the two groups were significantly larger when
compared with lower severity CIS-R groups.  
ROC analysis
In Table 5 we present our estimates from the ROC analysis. The ROC analysis selects the
optimal threshold below which participants are more likely to report “feeling better” rather
than “feeling the same”. The mean change in the group reporting “feeling better” (see 
Tables 1-3) is a good approximation for the threshold when the baseline symptom severity 
is moderate and high for all three instruments. However, when the depression severity is low, 
the threshold needs to be considerably lower than the mean change in order to optimise the
discrimination between the two groups (Figure Appendix 1a-1c). 
These results illustrate that at lower levels of depression severity it is much more difficult to
discriminate between “feeling better” and “feeling the same” for all three scales. The threshold 
was estimated at 2 points and was not greatly affected by baseline severity for the PHQ9. 
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The threshold score for the BDI-II was higher at low baseline severity at 5 points than 
for moderate and high CIS-R which was 4 points. Finally, the threshold score for GAD-7 
was 2 points for low and moderate CIS-R and 1 point for high CIS-R at time 1 (Table 5). 
What is more important, are the noticeably lower levels of sensitivity of patients’ GRS
response to identify improvements, when the baseline severity is low. This is true for all 
measures. At low baseline CIS-R, the sensitivity (Table 5) was 35%, 36% and 32% for 
PHQ9, BDI-II and GAD-7, respectively, indicating the proportion who reported they felt 
better and had experienced reductions larger than the threshold score. At higher baseline 
CIS-R, the patients who reported improvement had much higher chances (60% or more) to
show reductions larger than the threshold score in all scales.
It should also be noted that there is uncertainty in the presented values of the optimal
thresholds. These uncertainties are as large as the differences between these values across 
CIS-R groups. Thus, we do not have evidence that the threshold scores vary according to
severity. However, this implies that the threshold as a percentage reduction is increasing as 
the severity drops (Table 5). Uncertainty estimates of the sensitivity and specificity at the
optimal threshold are also presented in Table SA1.1 (Appendix 1). Statistics relevant to the
determination of the optimal threshold and effect size calculations, namely: standard 
deviations of baseline scores and changes scores are also presented in Table SA1.2 
(Appendix 1).  
Discussion
We have estimated the minimally clinically important difference using a patient-centred
approach for three commonly used scales used to assess depression and anxiety. 
We have estimated the reduction in scores during the previous 2 weeks in those who 
reported “feeling better”. We then estimated the difference between “feeling better” and 
“feeling the same” in terms of the reduction of scores. 
The finding that people who reported “feeling the same” also had a small reduction in
symptoms is not well understood (Robinson et al., 2017). The patients’ GRC is likely to
include constructs additional to those measured by the disease specific scales, so a perfect 
correlation is not expected.  Research in health related quality of life have also found that
retrospective measures of the patient’s view of change is sensitive to change in disease-
specific scales and correlates strongly with patient’s satisfaction with change but is not 
concordant with repeated current assessments of patients’ experience of change (Fischer
et al., 1999). This literature, also presents evidence that those with less severe dysfunction at
baseline have smaller change score over time, thus, variability on baseline dysfunction may 
also reduce the strength of association between change scores and the GRC (Stucki et al., 
1996). The reductions we observed in this study was proportionally more dramatic amongst 
those with lower severity. 
Finally, we also formulated the problem as trying to distinguish between “feeling better” and
“feeling the same” using ROC analysis to estimate the optimal threshold to provide separation. 
This final method seems the most robust as it can take account of the increased variability of
scores at the lower severity. 
In the lowest severity group, average reductions experienced by those reporting “feeling 
better” were estimated at 24.1%, 30.8% and 26.4% on the PHQ9 and BDI-II and GAD-7 
scales respectively. However, the optimal threshold required to discriminate between 
“feeling better” and “feeling the same” were reductions of 48%, 51.5% and 71% respectively.
The thresholds at the middle level severity were 21%, 23% and 26.8% respectively.
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
The marked increase of threshold in percentage terms is because the variability, particularly in
those “feeling better”, is relatively large in those at lower severity so this makes discrimination 
more difficult. 
In our previous work we found evidence that viewing the MCID as a proportion led to a more
constant value over the severity range (Button et al., 2015). However, this was based on
analyses informed by RCTs which excluded patients below a certain threshold score and 
similar distributions of baseline scores on the BDI scale. In this study with a sample with 
lower severity scores, it is apparent that there is still an increase in MCID in proportional 
terms at lower levels of severity, even if the absolute levels are relatively constant. It is
perhaps unsurprising that those with low scores will find it more difficult to distinguish 
between “feeling the same” and “feeling better”. These results bring to foreground the 
concept of reliability of change in outcome scales and its dependence with baseline severity. 
There it seems that baseline scores below certain thresholds render the quantification of
change in proportionate terms less informative with respect to patients’ retrospective 
evaluations. 
The use of ROC analysis also allowed the evaluation of performance of the ability of patients’
GRS scoring to identify change in outcomes frequently used in RCTs, at the  threshold score, 
namely overall discrimination (AUC) and sensitivity and specificity (Table 5, Table SA1.1).
Only a small proportion of people reporting improvement at low baseline severity actually
show reductions larger than the threshold score, in all scales (35%;36%; 32% for PHQ9, 
BDI-II and GAD-7, Table 5). This proportion is also significantly lower compared to the rest
of the CIS-R groupings, for all three outcome measures (Table SA1.1). This implies that even
if treatment effects are similar in those with less severe symptoms, it is much less likely that
they will experience any benefit.  This confirms that knowledge about treatment effects and
the MCID should allow, in principle, to determine whether an individual is likely to benefit from
a treatment. 
This is the first large cohort study in primary care exploring this question and to our
knowledge, there is only one study exploring a similar question and reached similar 
conclusions. This study used data from a small RCT and explored the question of the size 
of effect that could be considered as a successful treatment outcome (McMillan et al., 2010),
based on the reliable and clinically significant change (RCSC) index and using the PHQ9. 
The reported proportions of patients experiencing improvements was significantly reduced 
among asymptomatic patients (PHQ9<4) and found that the odds of improvement could be
affected by how the RCSC index was anchored e.g. how reliably patients’ change could be
discriminated against a clinical mean rather a non-clinical one.
It is striking that there are many similarities in how the different scales behave in relation 
to self-reported improvement. Previous meta-analytic work evaluating the relative 
responsiveness of eight scales (6 depression and 2 quality of life) also found little difference
between scales capturing change caused by treatment (Kounali et al., 2016). That study 
included a broad range of different treatments from RCTs and even though the absolute
values of the scales differed, the pattern of results was similar and the proportionate changes
seemed comparable.  
Strength and limitations
This is the first study of a large contemporary cohort drawn from a population seeking help 
for their symptoms in primary care in the UK. In contrast to our previous study that used data
from RCTs, this sample was not selected according to severity criteria so included less 
severe patients and also minimised any regression to the mean. We used a flexible 
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Bayesian approach towards estimation and were careful in ensuring the robustness of our
statistical models. In particular, our approach provided a realistic assessment of the 
distribution of change, which is critical for the determination of the optimal threshold through 
ROC analyses. These results enhance our earlier work by extending it to lower severities of
symptoms and to include other commonly used outcome measures, the PHQ9 and GAD-7.
Despite the size of this cohort, the number with low CIS-R baseline severity who report
“feeling better” at baseline is still rather small (n=36), so some of our estimates lacked
precision. Our method also relied on the use of self-reported improvement. It remains 
unclear how patients’ perceptions of change can inform therapeutic significance, but it is
certainly an aspect of this. It is also noteworthy that those who reported “feeling the same”
experienced a reduction in symptoms, and there was a marked asymmetry in this sample
such that feeling worse was not associated with such large changes as “feeling better”. 
The reasons for this are unknown. In our analyses we could take account of the changes in
those “feeling the same” when estimating the MCID. Using self-reported change as a “gold
standard” has good face validity (Malpass et al., 2016) and qualitative findings support its 
use. Yet our results indicate areas where our understanding of the responses requires 
further research.
Implications
Our results have three potential uses. Firstly, they have implications for sample size
calculations for RCTs using these outcomes. The MCID estimates can be used as a basis 
for sample size estimation if the likely values of the outcome at follow-up are known given 
that the MCID varies according to severity, at least in proportional terms. Our best estimates 
are the initial values given in Table 5. However, the application is not straightforward. Here 
we have estimated an average within-person change related to improvement but an RCT
compares groups. Application of our results would require a counterfactual argument in 
which researchers compare the same individual(s) who receive placebo but who might have
received the active treatment. The MCID estimated from a within person calculation can then
be applied to the between group differences in a clinical trial. 
The MCID estimates could ultimately guide decisions about whether a treatment will benefit 
an individual. For this, one needs to be able to predict the likely score for that person on the 
proposed outcome measure were they not to receive that treatment. This is available within 
an RCT design since treated and control patients are exchangeable and thus control subject
scores at follow-up provide us with a good guess on a patient’s potential outcome at follow-up.
We then compare the treated individual’s attained score at follow-up with the likely scores 
attained by the controls, to see if the likely treatment benefits exceed the MCID. Our results 
indicate that even if treatment effects are similar in those with less severe symptoms, it is
much less likely that they will experience any benefit.  
The third application is in interpreting the results of clinical trials. Using a similar argument, 
the MCID could be used to decide whether patients would experience a clinically meaningful
benefit from the treatment when the treatment effect is larger than the MCID. Characterisation 
of the profile of treated patients who experienced reductions larger than the MCID could also
be useful.  
There is currently much controversy about the benefits or otherwise of antidepressant
treatment, especially in those with less severe symptoms. We regard our approach here as
a step towards resolving this controversy using empirical data. In order for us to be confident
about recommending treatments to patients we will need more accurate information on
individualised treatment effects, the outcome without treatment as well as the MCID. 
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Appendix 1 
Beta Regression Model 
Beta regression modelling can have substantial advantages when outcomes are bounded and exhibit high levels of skewness. These include
substantial improvements in fit as well as increased precision for individual predictions. Beta regression also models outcomes on a 
multiplicative scale.
More importantly, beta regression allows us to simultaneously explore covariate effects not only on our expectations but also variability which is important
for the receiver operating curve (ROC parameters) estimation. The quantification of variability is very often un-appreciated and selectively reported if 
at all. This state of affairs is despite its importance in sample size calculations required for the design of RCTs as well as meta-analytic studies. Recent
methodological advances have allowed a more widespread use of generalised location/scale modelling such as mixed effects beta regression through standard 
statistical software and for more complex settings e.g. repeated measures analyses.
There is a difference between the regression model we used and a binary regression models where the outcome is whether the patient reports an improvement
as a function of the change in their depression scores. The former regression model assumes that the expected value of outcome score change depends on the 
patient’s view of their condition whereas the later assumes that the expected value of the patient’s view of how they feel depends on their change in scores of
BDI.  For this reason, we based the estimation of the required ROC parameters on the regression model we described in the previous section. 
Each of the outcomes Y=PHQ9, BDI-II and GAD-7 all of which are bounded within (a,b), where a=0 and b=27 for PHQ9; b=63 for BDI-II and 
b=21 for GAD-7 
We transformed the scale to (0,1) interval by applying the transformation Ynew=(Y-a)/(b-a)
The reparameterization used for modelling the mean and variance of the beta distribution follows Ferrari and Cribari-Neto (2004), had already 
appeared in the literature, for example in Jorgensen (1997) or in Cepeda (2001).
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Table SA1.2: Baseline SD and SD estimates for change  on the PHQ9, BDI-II and GAD-7 for the group reporting
feeling better
Feeling Better Feeling The Same
Outcome
Baseline 
CIS-R
SD
Baseline 95% CI
SD
Change 95%  CI
SD
Baseline 95%  CI
SD 
Change 95% CI
PHQ9 0-11 2.60 [2.20 3.06] 3.35 [2.86 3.89] 2.52 [2.16 2.93] 3.24 [2.81   3.70]
12-19 2.08 [1.79   2.43] 2.68 [2.35   3.07] 2.50 [2.18   2.86] 3.21 [2.86   3.60]
20+ 3.60 [2.91   4.24] 4.64 [3.80   5.40] 3.01 [2.66   3.40] 3.87 [3.50   4.25]
BDI-II 0-11 4.92 [4.04   5.90] 6.21 [5.21   7.31] 4.05 [3.40   5.09] 5.08 [4.39   5.85]
12-19 3.69 [3.15   4.25] 4.64 [4.04   5.26] 3.76 [3.24   4.72] 4.71 [4.12   5.39]
20+ 6.09 [4.88   7.42] 7.68 [6.24   9.15] 4.50 [3.76   5.65] 5.64 [4.82   6.53]
GAD-7 0-11 2.33 [1.90   2.82] 3.04 [2.51   3.64] 2.33 [1.97   2.71] 3.02 [2.61   3.47]
12-19 1.90 [1.63   2.21] 2.48 [2.15   2.84] 2.45 [2.14   2.80] 3.18 [2.81   3.60]
20+ 3.43 [2.76   4.03] 4.48 [3.69   5.14] 2.54 [2.06   2.99] 3.30 [2.71   3.84]
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Appendix 5 Usefulness of the PHQ-9 in primary
care to determine meaningful symptoms of low mood:
a qualitative study
See Malpass et al.39
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Appendix 6 Variation in recognition of happy and
sad facial expressions and self-reported depressive
symptom severity: a prospective cohort study
See Bone et al.40
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
Appendix 7 Variation in the recall of socially
rewarding information and depressive symptom
severity: a prospective cohort study
See Lewis et al.41
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Appendix 8 Why are there discrepancies between
depressed patients’ Global Rating of Change and
scores on the PHQ depression module? A qualitative
study of primary care in England
See Robinson et al.42
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Appendix 9 Comparison between
self-administered depression questionnaires and
patients’ own views of changes in their mood:
a prospective cohort study in primary care
Disagreement between self-administered depression questionnaires and patients’ own views 
of their recovery: a cohort study 
 
Background: Self-administered questionnaires are widely used in primary care and other 
clinical settings to assess the severity of depressive symptoms and monitor treatment 
outcomes. Qualitative studies have found that changes in questionnaire scores might not fully 
capture patients’ experience of changes in their mood but there are no quantitative studies of 
this issue.  
 
Aims: We examined the extent to which changes in scores from depression questionnaires 
disagreed with primary care patients’ perceptions of changes in their mood and investigated 
factors influencing this relationship.  
 
Methods: Prospective cohort study assessing patients on four occasions, two weeks apart. 
Patients (N=554) were recruited from primary care surgeries in three UK sites (Bristol, 
Liverpool and York) and had reported depressive symptoms or low mood in the past year 
(68% female, mean age 48.3 (SD 12.6)). Main outcome measures were changes in scores on 
Patient Health Questionnaire (PHQ-9) and Beck Depression Inventory (BDI-II) and the 
patients’ own ratings of change,  
 
Results: There was marked disagreement between clinically important changes in 
questionnaire scores and patient-rated change, with disagreement of 51% (95% CI 46% to 
55%) on PHQ-9 and 55% (95% CI 51% to 60%) on BDI-II. Patients with more severe 
anxiety were less likely, and those with better mental and physical health related quality of 
life more likely, to report feeling better, having controlled for depression scores. 
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Conclusion: Our results illustrate the limitations of self-reported depression scales to assess 
clinical change. Clinicians should be cautious in interpreting changes in questionnaire scores 
without further clinical assessment.  
Keywords: depression, primary care, PHQ-9, BDI-II, cohort. 
 
Introduction 
Self-administered screening questionnaires that assess the severity of depressive symptoms 
have been recommended in UK primary care and in North America and some parts of 
59,60. These recommendations were made in response to concerns that depression is 
under-diagnosed and under-treated in primary care, with the aim of improving detection and 
monitoring treatment response. In 2006 the Quality Outcomes Framework (QOF) in the UK 
incentivised the use of three questionnaires: the Patient Health Questionnaire (PHQ-9), the 
Beck Depression Inventory (BDI-II) and the Hospital Anxiety and Depression Scale 
(HADS). These questionnaires are no longer incentivised but remain widely used in UK 
primary care and continue to influence treatment decisions  59. The PHQ-9 along with other 
questionnaires is also used as a routine outcome measure in Improving Access to 
Psychological Therapies (IAPT) services in the UK 61. 
 
Self-administered depression questionnaires have been compared to diagnostic assessments 
and their sensitivity and specificity is fairly good, at around 80% 62,63. However, their use  in 
clinical settings has been criticized 64,65.  One concern is that changes in scores might not 
fully capture the patient’s experience of improvement or deterioration in their mood. Such 
disagreement has important implications for treatment decisions and patient-centred care 66,67. 
Europe 
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Clinicians routinely ask patients whether their condition has improved, deteriorated or stayed 
the same 68,69. Patient-rated change is measured in research settings with a single-item 
question, which asks patients retrospectively about how their whole condition has changed 
compared to a previous occasion, rather than asking about individual symptoms 68,69. 
 
We have conducted qualitative studies of people whose self-rated changes in mood differed 
from their responses to self-administered depression scales 66,67. Patients explained the 
disagreement as resulting from the presence of co-morbid conditions, negative and positive 
life events, changes in social support and changes in quality of life 66.  This supports other 
qualitative findings that patients often state that scales such as the PHQ-9 do not fully capture 
their experience of illness 67. We are not aware of any similar qualitative or quantitative 
investigations of this question.  
 
In this study we used a cohort of patients recruited from primary care to investigate the extent 
to which responses to the PHQ-9 and Beck Depression Inventory (BDI-II) disagreed with 
patients’ perceptions of changes in their mood, assessed using a patient-rated change scale. 
We also investigated factors that might influence patient reports of self-improvement having 
controlled for their responses on the PHQ-9 and BDI-II.  
 
 
Methods 
Participants 
Participants were recruited from General Practice (GP) surgeries in three UK sites: Bristol, 
Liverpool and York. Computerised records were used to identify patients aged 18 to 70 who 
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had reported low mood, depressive episodes, depressed mood, depressive symptoms or a 
major depressive episode in the past year, irrespective of any treatment. We excluded patients 
who: were diagnosed with bipolar disorder, psychosis or eating disorder; had alcohol or 
substance use problems; were unable to complete study questionnaires; or were 30 weeks or 
more pregnant. 7,721 patients were sent an information letter and 1,470 (19%) replied. Of 
these, 821 were willing to be contacted, 23 (3%) of whom were ineligible. The remaining 798 
were contacted to arrange an interview. Of these, 563 consented (38%) and 559 (38%) were 
interviewed (4 could not be contacted). Data were collected at four time-points, two weeks 
apart (baseline and follow-up 1, 2 and 3). Patients and public representatives were involved 
in management and steering groups for the PANDA programme grant and gave input into the 
design, conduct and interpretation of the study. 
 
Ethical Approval 
All participants provided written informed consent and ethical approval was obtained from 
NRES Committee South West - Central Bristol. The authors assert that all procedures 
contributing to this work comply with the ethical standards of the relevant national and 
institutional committees on human experimentation and with the Helsinki Declaration of 
1975 as revised in 2008. 
 
Measures 
Depressive symptoms: The Patient Health Questionnaire (PHQ-9) and Beck Depression 
Inventory-II (BDI-II) were completed at each time-point. The PHQ-9 is a 9-item
self-administered measure of depressive symptoms in the past two weeks and scores range  
0-27 70. Internal consistency was high at each time-point (Cronbach’s alpha 0.89 to 0.92). from
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The BDI-II is a 21-item self-administered measure of the severity of depressive symptoms in 
the past two weeks 63 and scores range from 0 to 63. Internal consistency was high at each 
time-point (Cronbach’s alpha 0.93 to 0.95). Higher scores indicate more severe depressive 
symptoms. 
 
Patient-rated change: We used a single-item question based on ‘Global Rating Scales’ that 
are routinely used in musculoskeletal and chronic pain research and have high reliability and 
validity 68,69. Participants were asked ‘compared to when we last saw you 2 weeks ago how 
have your moods and feelings changed?’ Response options were: ‘I feel a lot better’ (1), 
‘I
 
feel slightly better’ (2), ‘I feel about the same’ (3), ‘I feel slightly worse’ (4), ‘I feel a lot 
worse’ (5). We used ‘moods and feelings’ instead of ‘depression’ because many people might 
not consider themselves “depressed” and this wording should encourage a more general 
response. Our qualitative studies found evidence that patients viewed this question as more 
open-ended and explorative, stating that it allowed them to ‘sum up’ their mental health and 
express themselves outside of the parameters of the questionnaires 66. The patient-rated 
change scale was completed twice at each time-point, at the beginning and end of the 
questionnaire. Test-retest reliability was good with kappa (quadratic weights) of 0.89. The 
scale, or similar, has been used in prior Randomised Controlled Trials 66,67,71. 
Anxiety: The Generalised Anxiety Disorder Assessment (GAD-7) 72 was completed at each 
time-point and is a 7-item self-administered measure of the severity of anxiety symptoms in 
the past two weeks,  scores ranging from 0 to 21. Higher scores indicate more severe 
symptoms. 
 
Physical and Mental Health-Related Quality of Life: The 12-item Short-Form Health Survey 
(SF-12) 73 was administered at each time-point. Separate physical and mental health-related 
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quality of life scores were derived 73. Scores range from 0 to 100, higher scores indicating 
better quality of life. 
 
Negative Life Events:  At baseline (only), participants were asked, using a self-administered 
computerized questionnaire, whether they had experienced the following in the previous
6 months: (i) bereavement,  (ii) separation or divorce, (iii) a serious illness or injury,
(iv) victimisation (mugging, burglary, serious assault), (v) being in trouble with the law, 
(vii) a serious dispute with a family member or friend, or (viii) being made 
redundant from work. Due to the low frequency, a binary variable was created 
(none or 1 or more).  
 
Social Support: At baseline (only), participants completed eight questions as part of the self-
administered computerized questionnaire relating to: (i) feeling loved, (ii) having others that 
can be relied on, (iii) feeling accepted, (iv) feeling supported, (v) having others to talk to, 
having others that make them happy, (vii) having others that care what happens to them,
and (viii) having others that make them feel an important part of their lives. Each question 
three-point scale (1) not true, (2) partly true, and (3) certainly true. Scores were 
summed and ranged from 1 to 24, higher scores indicating more social support.  
 
Potential confounders: We adjusted for variables previously shown to be associated with 
depressive symptoms, and site. Demographic variables (age, sex, ethnicity, employment 
status, financial status, and education level) were measured at baseline. Due to small 
numbers, ethnic minority status was a binary variable. Employment status was categorised as 
employed, unemployed not by choice, and unemployed by choice. Financial status was three 
categories: low (‘Finding it very difficult to make ends meet’ and ‘Finding it difficult to make 
(vi) debt,
compulsorily
(vi) 
used a 
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ends meet’), medium (‘Just about getting by’) and high (‘Living comfortably’ and ‘Doing 
alright’). Education level was seven categories, from no qualifications to higher degree. 
 
Statistical Analyses 
Identifying disagreement between questionnaire scores and patient-rated 
change  
To calculate change scores, mean PHQ-9 and BDI-II scores at each follow-up time-point 
were subtracted from mean scores at the previous time-point (to correspond to the patient-
rated change scale which asks about change over the last two weeks). Possible change scores 
ranged from -27 to +27 for PHQ-9 and -63 to +63 for BDI-II. Greater negative scores 
indicated improvement and greater positive scores indicated deterioration. 
 
We used the Minimal Clinically Important Difference (MCID), the smallest change in 
symptoms meaningful to patients, to assess extent of disagreement 71. The MCID has been 
estimated in the PANDA cohort to be around a 20% reduction in PHQ-9 or BDI-II scores 
(manuscript in preparation). We used the MCID of a 20% reduction or increase in 
questionnaire scores to create the following categories: clinically important decreases  
(a decline in scores of 20% or more ), no clinically important change (a decline or increase in 
scores smaller than 20% ), and clinically important increases (an increase in scores greater 
than or equal to 20%) 71. For each response option on the patient-rated change scale, we 
report the proportion of patients in each of the above MCID categories.   
 
We defined disagreement as (i) a clinically important change in PHQ-9/ BDI-II scores and a 
rating of change response that indicated either no change or a change in the opposite direction 
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(ii) no clinically important change in PHQ-9/ BDI-II scores and a rating of change response 
that indicated a change in either direction. The proportion of patients showing some form of 
disagreement overall was calculated overall by dividing the total number of people showing 
disagreement by the total number of people. Proportion disagreement was also calculated 
within each patient-rated response category. Quadratic weighted and unweighted kappa 
values were used to test agreement between patient rating of change responses and MCID 
categories. In a prior manuscript we had identified a MCID of 15% for the BDI-II 71 so we 
conducted sensitivity analyses with this estimate. 
 
Reliability of disagreement  
We further examined the extent of disagreement by tabulating the proportion of participants 
scoring within each category of the patient-rated change scale with the equivalent proportion 
scoring a corresponding change on the PHQ-9/BDI-II (supplementary analyses).  For 
example if 10% of patients reported feeling much better, this was tabulated against the top 
10% of change scores on the PHQ9/BDI-II and so on for the percentage who reported 
feeling slightly better, the same, slightly worse or worse. Quadratic weighted and unweighted 
kappa values were used to test agreement between these proportions. 
 
Variables that influence disagreement 
We used a binary outcome (feeling better versus same or worse) to reflect that neither feeling 
the same nor worse is a good clinical outcome. As the patient-rated change scale asks about 
the last two weeks, we could construct logistic models with the 2, 4 or 6 week follow-up as the
outcome. We adjusted for binary clinically important change (20% change in scores or not)
over the previous two-weeks. This binary variable reduced collinearity between 
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depression scores and other exposures (e.g. anxiety) and was consistent with our approach to 
clinically important change and disagreement.  
 
For exposures measured at multiple time-points (anxiety, mental and physical-health related 
quality of life,) we did a principal components analyses of the exposure at the current and 
preceding time-points. Principal components analysis (PCA) can be used to transform two 
correlated variables into orthogonal (uncorrelated) factors or ‘principal components.’ The 
first component is a function of the average score on each variable. The second component  
is uncorrelated with the first, and is a function of the difference between two scores 74. 
were adjusted for confounders known to be associated with depressive symptoms 
ethnicity, education level, current use of antidepressants and marital, financial and 
employment status) and site. All analyses were conducted using STATA 14. 
Role of the funding source 
The funding source had no role in study design, data collection, data analysis, interpretation 
or writing of the report. The corresponding author had full access to all data used in the study, 
and final responsibility for the decision to submit for publication. 
 
Results 
Due to extensive missing data at baseline 5 patients were excluded, leaving 554 for analyses. 
At follow-ups one, two, and three: 476 (86%); 443 (80%), and 430 (78%) provided data 
respectively.  Baseline sample characteristics are presented in Table 1. Patients were aged 18 
to 71 (mean 48·30, SD 12·56), 68% female and 96% white.  
(age, sex,
Models
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Identifying disagreement between questionnaire scores and patient-rated 
change  
Disagreement between questionnaire scores and the patient-rated change scale was similar 
across time-points, so data from baseline to follow-up 1 are presented for brevity.  
 
Depression change scores according to patient-rated change 
Change in depression questionnaire scores were related to patients’ responses on the rating 
scale. Patients who reported ‘feeling a lot better’ had the largest mean decrease in scores, and 
patients who reported ‘feeling a lot worse’ the largest increase (Table 2, first row in PHQ9 
and BDI-II sections).  
 
Clinically important change in depression scores according to patient-rated change 
When clinically important differences in depression scores were compared to patient ratings, 
there was evidence of disagreement. The proportion of patients showing each type of 
clinically important change in questionnaire scores (increase, no change, decrease), in 
comparison to their responses is presented in Table 2.   
 
Disagreement was most common in patients who reported feeling worse on the patient-rated 
change scale. PHQ-9 scores showed no change or an improvement for 76% (95% CI: 66% to 
83%) of those who reported ‘feeling slightly worse’, and 81% (95% CI: 54% to 94%) of 
those who reported ‘feeling a lot worse’ (Table 2, last row in PHQ-9 section). These results 
were very similar for the BDI-II (Table 2, last row in BDI-II section). Disagreement was also 
common in patients who reported feeling better. PHQ-9 scores remained the same or 
deteriorated in 65% (95% CI: 55% to 74%) of those who reported ‘feeling slightly better’, 
and 53% (95% CI: 37% to 67%) of those who reported ‘feeling a lot better’ (Table 2, last row 
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in PHQ-9 section).  Disagreement was lower for patients who reported feeling better on the 
BDI-II: 43% (95% CI: 34% to 53%) for those reporting feeling slightly better and 28%  
16% to 43%) for those reporting feeling much better (Table 2, last row in BDI-II 
Overall, the proportion of people showing some form of disagreement was 51% 
46% to 55%) on the PHQ-9 and 55% (95% CI: 51% to 60%) on the BDI-II. 
When  using a more stringent minimal clinically important difference of 15%, results were
comparable (Supplementary Table 1). 
 
Quadratic weighted Kappa scores indicated agreement between patient ratings and the 
categories generated from the change scores ranging from 81·2-83·6% for the PHQ-9 and 
78·6-83·1% the BDI-II.  Unweighted Kappa scores indicated low levels of agreement (3·9-
7·6%) for PHQ-9 and BDI-II. 
 
Reliability of disagreement 
Results were similar when the proportion of patients scoring within each category of the 
patient-rated change scale were compared with the relative proportion of patients scoring 
within these ranges on the PHQ-9 and BDI-II (Supplementary Table 2). High agreement was 
observed between the patient-rated change scale and PHQ-9/BDI-II, with weighted kappa 
values indicating agreement ranging from to 91·4% to 93·1% across time-points. Unweighted 
kappa values indicated poorer agreement (37·9-42·4%). We found no evidence that 
disagreement differed according to gender (results available on request). 
 
Variables that influence disagreement  
Results for the PHQ-9 are shown in Table 3 and for the BDI-II, Table 4. We found evidence 
that an increase in anxiety symptoms was associated with a decreased odds of reporting 
(95% CI:
section). 
(95% CI:
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feeling better after controlling for changes in depressive symptoms. This was consistent 
across time-points, for PHQ-9 and BDI-II. For example at follow-up 1, a four-point increase 
in anxiety scores was associated with a 0·67 (95% CI 0·55 to 0·82) decrease in the odds of 
feeling better, having controlled for change in PHQ-9 scores. 
 
We also found consistent evidence that improved mental and physical health related quality 
of life was associated with increased odds of reporting feeling better after controlling for 
changes in depressive symptoms. For example at follow-up 1, an eight-point increase in 
mental health related quality of life was associated with a 1·43 (95% CI 1.11 to 1.61) 
increase in the odds of feeling better. For physical health related quality life this odds ratio 
was 1.28 (1.08 to 1.54). There was no evidence of an influence of negative life events or 
social support on the likelihood of reporting improvement (Tables 3 and 4). We found no 
evidence that any of these associations differed according to gender (available on request). 
 
 
 
 
Discussion 
Summary of findings 
We found evidence that changes in scores on self-administered depression questionnaires 
often differ from patients’ own views of changes in their mood. Over 50% of people 
evidenced some form of disagreement between their questionnaire scores and self-rated 
mood. Even though, on average, there is fairly good agreement between change in depressive 
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symptoms and self-rated changes in mood, our results suggest that applying these 
questionnaires to individual patients will be prone to error. 
  
Patients with more severe anxiety symptoms were less likely, and those with better mental 
and physical health related quality of life more likely, to report feeling better having 
controlled for their depression questionnaire scores. Our results support the idea that 
self-administered scales only capture a subset of the subjective experience that contributes  
to patient-rated change and suggests that relying solely upon responses to self-administered 
scales could be misleading in a large proportion of situations.  
 
Strengths and Limitations 
We set broad and inclusive entry criteria to reflect the patients consulting for depression in 
primary care. The Minimal Clinically Important Difference (MCID) allowed us to infer that 
differences were clinically important, though we acknowledge that the MCID is itself an 
average determined by reference to patients self-rated change. Our results indicate that such 
average MCIDs are difficult to apply in individual cases, even if they are valuable overall in 
planning and interpreting studies. 
 
The depression questionnaires and patient-rated change scale will be subject to measurement 
error, which could be a potential source of disagreement. Multi-item scales with specific 
prompts might be more reliable 68, but the reliability of the patient-rated change scale was 
good. There could be other reasons for disagreement. The patient-rated change scale asks 
retrospectively about change and recall might be poor 75. However, the recall period  
(2 weeks) was the same for the depression questionnaires and patient-rated change scale. 
‘Response shift’ is the concept that answers will differ across time not because the condition 
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has changed but because the opinion on what the condition means has changed 76. This might 
also lead to disagreement, if it occurred. Finally, it is unclear which aspects of the patients’ 
condition have informed response to the patient-rated change scale. However, these points 
are largely concerned with explaining differences between the two contrasting approaches to 
assessment rather than casting doubt on our conclusions.  
 
There was a low response rate for the study and this might have affected the representativeness 
of our target population which was patients seeking help in primary care. However, it seems
unlikely that our method of recruitment and the low response rate would inflate the level of
disagreement although we cannot rule out that possibility. Our sample was from the UK and
predominantly white and this may limit generalizability. Finally, there was attrition though
retention was good with 78% at the final follow-up. 
 
These quantitative findings are partly consistent with our previous qualitative findings 66,67. 
Of course, the PHQ-9 and BDI-II only measure depression symptoms so it is unsurprising 
that anxiety should affect patient-rated change in mood and feelings independently. Given the 
co-occurrence of depression and anxiety it is important to recognize that, from the patients’ 
perspective, changes in anxiety will also be important.  
The PHQ-9 and BDI-II are recommended for assessment of depressive illness and treatment 
response in UK primary care and other clinical settings. Our results emphasise the importance 
of using these measures alongside clinical assessments that take in the perspective of the 
patient. Sole reliance upon information from self-administered questionnaires can potentially
be misleading and ignores areas that patients’ regard as important. Our evidence supports
the widespread scepticism among physicians about using self-administered questionnaires
in clinical practice 64. We provide quantitative evidence that the results of these
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questionnaires need to be interpreted along with other clinical assessments and should not
be relied upon alone. Our findings support the concept of ‘personal recovery’, developed 
in mental health services but also relevant in primary care 77,78. Personal recovery 
emphasizes the importance of a holistic focus on patients’ broad experiences rather than a 
restricted focus on ‘clinical recovery’ or symptom change. This makes the patients’ voice  
of central importance and there are efforts under-way to devise better measurements of 
patient-reported recovery.  
 
Some patients view self-administered questionnaires positively and request them to monitor 
their recovery 79. Questionnaires can, therefore, play a useful role in outcome assessment, in 
conjunction with clinical assessment that takes account of more holistic changes in mood. 
They are also useful as a guide for service level outcome assessment 61. In clinical trials, 
self-administered questionnaires are widely used for comparing groups and such randomized 
comparisons should be unbiased. Our findings suggest, though, that additional questions 
should also be used to assess the outcome of treatments in research studies.  
 
Future research could examine the generalizability of our findings to international settings 
and mental health services, and the relationship between patient-rated change and other 
mental health measures including the outcomes used in the NHS Improving Access to 
Psychological Therapy (IAPT) services 61. Future clinical trials could also use the 
patient-rated change in mood question as an outcome that might help to address the
limitations of existing measures. 
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Table 2: Change in depression severity according to the patient-rated change scale, compared to
clinically important changes in PHQ-9 and BDI-II scores. Disagreement (differing indications of change
symptoms) is shaded in grey (n = 465 PHQ-9, n = 468 BDI-II). 
 Patient-rated change scale 
Feeling a lot 
better 
Feeling slightly 
better 
Feeling about 
the same 
Feeling slightly 
worse 
Feeling a lot 
worse 
PHQ-9      
Mean (SD) change –3·4 (4·1) –2·7 (3·9) –·26 (3·6) 1·3 (4·3) 1·6 (5·4) 
CID Decrease, n (%)a 19 (47%) 34 (35%) 29 (14%) 9 (9%) 2 (13%) 
No CID Change, n (%)a 20 (50%) 56 (58%) 149 (70%) 65 (66%) 11 (69%) 
CID Increase, n (%)a 1 (3%) 7 (7%) 36 (16%) 24 (25%) 3 (18%) 
Disagreement, n (%)b 21 (53%) 63 (65%) 65 (30%) 74 (75%) 13 (82%) 
BDI-II      
Mean (SD) change  –8·0 (8·9) –5·6 (6·5) –1·2 (5·8) 0·0 (5·7) 3·2 (7·1) 
CID Decrease, n (%)a 29 (72%) 55 (57%) 74 (34%) 21 (22%) 3 (18%) 
No CID Change, n (%)a 9 (23%) 33 (34%) 92 (42%) 48 (49%) 9 (53%) 
CID Increase, n (%)a 2 (5%) 9 (9%) 51 (24%) 28 (29%) 5 (29%) 
Disagreement, n (%)b 11 (28%) 42 (43%) 125 (58%) 69 (71%) 12 (71%) 
CID = Clinically Important Difference based on the Minimal CID (MCID).  
aPercentages represent the proportions of patients showing differing CID changes (decrease, no change, increase) 
within each category of the global rating of change scale. 
bPercentages represent the proportions of patients showing disagreement within each category of the global 
rating of change scale
in depressive 
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Table 3. Association between exposure variables and the odds of reporting feeling 
better (versus the same or worse), adjusted for change on the PHQ-9 
Exposure variable 
 
Odds ratio for reporting feeling better (versus the same or worse),  
95% confidence interval and p value (n=375) 
Anxiety symptomsa Unadjusted  
Baseline to follow-up 1 Follow-up 1 to 2 Follow-up 3 to 4 
     Feeling same or worse ref ref ref 
     Feeling better ·67 (·55 to ·82) ·<.0001 ·65 (·53 to ·79) <·0001 ·71 (·59 to .86) <·0001 
 Adjustedd  
     Feeling same or worse ref ref ref 
     Feeling better ·66 (.54 to ·82) ·016 ·61 (·49 to ·76) <·0001 .72 (.60 to .97) ·001  
Mental health related 
quality of lifea 
Undjusted  
     Feeling same or worse ref ref ref 
     Feeling better 1·34 (1·11 to 1·61) ·002 1·33 (1·11 to 1·59) ·002 1·38 (1·15 to 1·64) ·000 
 Adjustedd  
     Feeling same or worse ref ref Ref 
     Feeling better 1·32 (1·08 to 1·61) ·006 1·38 (1·14 to 1·66) ·001 1·40 (1·17 to 1·68) <·000 
Physical health related 
quality of lifea 
Unadjusted  
     Feeling same or worse ref ref Ref 
     Feeling better 1·28 (1·07 to 1·54) ·007 1·25 (1·06 to 1·48) ·009 1·20 (1·01 to 1·42) ·039 
 Adjustedd  
 
     Feeling same or worse Ref Ref Ref 
     Feeling better 1·32 (1·08 to 1·60) ·006 1·32 (1·10 to 1·58) ·002 1·19 (·99 to 1·43) ·057 
Negative life eventsb Unadjusted  
 
     Feeling same or worse ref ref ref 
     Feeling better ·98 (·61 to 1·59) ·94 1·13 (·72 to 1·79) ·59 1·17 (·74 to 1·85) ·50 
 Adjustedd  
 
     Feeling same or worse Ref Ref Ref 
     Feeling better ·99 (·60 to 1·65) ·98 1·11 (·69 to 1·78) ·76 1·15 (·72 to 1·85) ·56 
Social supportc 
 
Unadjusted odds Ratio (95% CI) p value 
     Feeling same or worse Ref Ref ref 
     Feeling better 1·07 (1·00 to 1·14) ·067 1·01 (·95 to 1·07) ·71 1·02 (·96 to 1·08) ·56 
 Adjustedd  
 
     Feeling same or worse Ref Ref Ref 
     Feeling better 1·07 (1·00 to 1·15) ·045 1·02 (·96 to 1·08) ·59 1·01 (·95 to 1·08) ·76 
aFor exposures measured at every time-point (anxiety and quality of life), odds ratios represent the odds of reporting feeling 
better for each four-point increase in anxiety symptoms over time (on a factor score obtained using principal components 
analysis), adjusted for a binary indicator of meaningful change on the PHQ9. 
bNegative life events was measured at baseline only. The odds ratio represents the odds of feeling better in those who 
reported one life event or more compared to those who reported no life events, adjusted for a binary indicator of meaningful 
change on the PHQ9. 
cSocial support was measured at baseline only. The odds ratio represents the odds of reporting feeling better for each 
standard deviation increase in social support, adjusted for a binary indicator of meaningful change on the PHQ9. 
dAdjusted for age, sex, ethnicity, site, education level, current use of antidepressants and marital, financial and employment 
status 
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Table 4. Association between exposure variables and the odds of reporting feeling better 
(versus the same or worse), adjusted for change on the BDI-II 
Exposure variable 
 
Odds ratio for reporting feeling better (versus the same or worse),  
 95% confidence interval and p value (n=375) 
Anxiety symptomsa Unadjusted 
 Baseline to follow-up 1 Follow-up 1 to 2 Follow-up 3 to 4 
     Feeling same or worse ref ref ref 
     Feeling better ·67 (·56 to ·81) <·0001 ·67 (·56 to ·81) <·0001 ·70 (·59 to ·84) <·0001 
 Adjustedc  
     Feeling same or worse Ref ref Ref 
     Feeling better ·65 (·53 to ·81) <·0001 ·61 (·49 to ·76) <·0001 ·71 (·59 to ·86) <·0001 
Mental health related quality 
of lifea 
Undjusted  
     Feeling same or worse ref ref ref 
     Feeling better 1·37 (1·13 to 1·65) ·001 1·33 (1·12 to 1·58) ·001 1·38 (1·16 to 1·64) <·0001 
 Adjustedd  
     Feeling same or worse ref ref ref 
     Feeling better 1·34 (1·10 to 1·63) ·004 1·38 (1·14 to 1·66) ·001 1·38 (1·16 to 1·64) <·0001 
Physical health related 
quality of lifea 
Unadjusted  
     Feeling same or worse ref ref ref 
     Feeling better 1·25 (1·04 to 1·49) ·016 1·24 (1·05 to 1·46) ·013 1·22 (1·03 to 1·45) ·021 
 Adjustedd  
 
     Feeling same or worse Ref Ref Ref 
     Feeling better 1·27 (1·05 to 1·54) ·015 1·30 (1·08 to 1·55) ·005 1·22 (1·02 to 1·47) ·030 
Negative life eventsb 
 
Unadjusted 
     Feeling same or worse ref ref Ref 
     Feeling better 1·03 (·64 to 1·66) ·89 1·18 (·75 to 1·85) ·49 1·14 (·71 to 1·81) ·59 
 Adjustedd  
 
     Feeling same or worse ref Ref Ref 
     Feeling better 1·04 (·63 to 1·72) ·87 1·15 (·72 to 1·85) ·55 1·11 (·68 to 1·79) ·68 
Social supportc 
 
Unadjusted 
     Feeling same or worse ref Ref Ref 
     Feeling better 1·07 (1· to 1·14) ·06 1·01 (·95 to 1·07) ·71 1·02 (·96 to 1·09) ·52 
 Adjustedd 
 
     Feeling same or worse ref Ref Ref 
     Feeling better 1·07 (1·00 to 1·15) ·044 1·02 (·96 to 1·08) ·59 1·01 (·95 to 1·08) ·70 
aFor exposures measured at every time-point (anxiety and quality of life), odds ratios represent the odds of reporting feeling 
better for each four-point increase in anxiety symptoms over time (on a factor score obtained using principal components 
analysis), adjusted for a binary indicator of meaningful change on the PHQ9. 
bNegative life events was measured at baseline only. The odds ratio represents the odds of feeling better in those who 
reported one life event or more compared to those who reported no life events, adjusted for a binary indicator of meaningful 
change on the PHQ9. 
cSocial support was measured at baseline only. The odds ratio represents the odds of reporting feeling better for each 
standard deviation increase in social support, adjusted for a binary indicator of meaningful change on the PHQ9. 
dAdjusted for age, sex, ethnicity, site, education level, current use of antidepressants and marital, financial and employment 
status 
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Appendix 10 A randomised controlled trial
assessing the severity and duration of depressive
symptoms associated with a clinical significant
response to sertraline versus placebo, in people
presenting to primary care with depression (PANDA
trial): study protocol for a randomised controlled trial
See Salaminios et al.43
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Appendix 11 The clinical effectiveness of
sertraline in primary care and the role of depression
severity and duration (PANDA): a pragmatic,
double-blind, placebo-controlled randomised trial
See Lewis et al.44
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Appendix 12 Cost-effectiveness of sertraline in
primary care according to initial severity and duration
of depressive symptoms: findings from the PANDA
randomised controlled trial
See Hollingworth et al.45
DOI: 10.3310/pgfar07100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Duffy et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
EME
HS&DR
HTA
PGfAR
PHR
Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
